<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nephrol Dial Transplant</journal-id><journal-id journal-id-type="publisher-id">ndt</journal-id><journal-id journal-id-type="hwp">ndt</journal-id><journal-title>Nephrology Dialysis Transplantation</journal-title><issn pub-type="ppub">0931-0509</issn><issn pub-type="epub">1460-2385</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19028750</article-id><article-id pub-id-type="pmc">2639334</article-id><article-id pub-id-type="doi">10.1093/ndt/gfn464</article-id><article-id pub-id-type="publisher-id">gfn464</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Baseline characteristics of an incident haemodialysis population in Spain: results from ANSWER&#x02014;a multicentre, prospective, observational cohort study</article-title><alt-title alt-title-type="left-running">R. P&#x000e9;rez-Garc&#x000ed;a <italic>et al</italic>.</alt-title><alt-title alt-title-type="right-running">ANSWER study: Spanish incident haemodialysis population</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>P&#x000e9;rez-Garc&#x000ed;a</surname><given-names>Rafael</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mart&#x000ed;n-Malo</surname><given-names>Alejandro</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Fort</surname><given-names>Joan</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Cuevas</surname><given-names>Xavier</given-names></name><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Llad&#x000f3;s</surname><given-names>Fina</given-names></name><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Lozano</surname><given-names>Javier</given-names></name><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Garc&#x000ed;a</surname><given-names>Fernando</given-names></name><xref ref-type="aff" rid="af6">6</xref></contrib><contrib contrib-type="author"><collab>on behalf of all Investigators from the ANSWER study</collab></contrib></contrib-group><aff id="af1"><label>1</label><addr-line>Servicio de Nefrologia</addr-line>, <institution>Hospital Gregorio Mara&#x000f1;&#x000f3;n</institution>, <addr-line>Madrid</addr-line></aff><aff id="af2"><label>2</label><addr-line>Servicio de Nefrologia</addr-line>, <institution>Hospital Reina Sofia</institution>, <addr-line>Cordoba</addr-line></aff><aff id="af3"><label>3</label><addr-line>Servicio de Nefrologia</addr-line>, <institution>Hospital Vall d&#x02019;Hebron</institution></aff><aff id="af4"><label>4</label><addr-line>Servicio de Nefrologia</addr-line>, <institution>Hospital Consorci Sanitari de Terrassa</institution></aff><aff id="af5"><label>5</label><addr-line>Amgen S.A., Barcelona</addr-line></aff><aff id="af6"><label>6</label><addr-line>Unidad de Epidemiolog&#x000ed;a Clinica</addr-line>, <institution>Hospital Puerta de Hierro</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country></aff><author-notes><corresp id="COR1"><italic>Correspondence and offprint requests to</italic>: Rafael P&#x000e9;rez-Garc&#x000ed;a, Servicio de Nefrolog&#x000ed;a, Hospital Gregorio Mara&#x000f1;&#x000f3;n, C/Doctor Esquerdo, 46-28007 Madrid, Spain. Tel: <phone>+34-915-86-80-47</phone>; Fax: <fax>+34-915-86-83-18</fax>; E-mail: <email>rperezgarcia@senefro.org</email></corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>21</day><month>11</month><year>2008</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>11</month><year>2008</year></pub-date><volume>24</volume><issue>2</issue><fpage>578</fpage><lpage>588</lpage><history><date date-type="received"><day>21</day><month>12</month><year>2007</year></date><date date-type="accepted"><day>22</day><month>7</month><year>2008</year></date></history><permissions><copyright-statement>&#x000a9; The Author [2008].</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Oxford University Press</copyright-holder><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/"><p>The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org</p></license></permissions><abstract><p><bold>Background.</bold> The ANSWER study aims to identify risk factors leading to increased cardiovascular morbidity and mortality in a Spanish incident haemodialysis population. This paper summarizes the baseline characteristics of this population.</p><p><bold>Methods.</bold> A prospective, observational, one-cohort study, including all consecutive incident haemodialysis patients from 147 Spanish nephrology services, was conducted. Patients were enrolled between October 2003 and September 2004. Sociodemographic, clinical, laboratory and health care characteristics were collected.</p><p><bold>Results.</bold> Baseline characteristics are described for 2341 incident haemodialysis patients [mean (SD) age 65.2 (14.5) years, 63% males]. The main cause of renal failure was diabetic nephropathy (26%). The majority of patients (57%) had a Karnofsky score of 80&#x02013;100 and 27% were followed up by a nephrologist for &#x02264;6 months. In total, 86% of the patients had hypertension, 43% had dyslipidaemia and 44% had a history of cardiovascular disease. Initial vascular access was obtained via a temporary catheter in 30% of patients, via a permanent catheter in 16% and via an arteriovenous fistula in 54%. Albumin levels were &#x0003c;3.5 g/dl in 43% of patients. Immediately prior to the onset of haemodialysis, the mean (SD) glomerular filtration rate (GFR) was 7.6 (2.8) ml/min/1.73 m<sup>2</sup>, and only 6.7% of the patients were within the K/DOQI guidelines for all four bone mineral markers. In addition, a high proportion of patients had anaemia markers outside the EBPG guidelines (haemoglobin &#x0003c;11 g/dl, 59%, ferritin &#x0003c;100 or &#x0003e;500 ng/ml, 41% and saturated transferrin &#x0003c;20 or &#x0003e;40%, 50%) despite previous treatment with erythropoiesis-stimulating agents in 41% of cases.</p><p><bold>Conclusions.</bold> There is excessive use of temporary catheters and a high prevalence of uraemia-related cardiovascular risk factors among incident haemodialysis patients in Spain. The poor control of hypertension, anaemia, malnutrition and mineral metabolism and late referral to a nephrologist indicate the need for improving the therapeutic management of patients before the onset of haemodialysis.</p></abstract><kwd-group><title>Keywords</title><kwd>cardiovascular</kwd><kwd>haemodialysis</kwd><kwd>malnutrition</kwd><kwd>risk factors</kwd><kwd>vascular access</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="S1"><title>Introduction</title><p>Haemodialysis has become an increasingly safe and well-tolerated therapy for patients with end-stage renal disease (ESRD). Nevertheless, life expectancy of dialysis patients remains significantly shorter than that of the general population with similar demographics [<xref ref-type="bibr" rid="R1">1</xref>]. There is also a high incidence of cardiovascular morbidity and mortality in this population [<xref ref-type="bibr" rid="R2 R3">2,3</xref>]. Large, prospective, observational studies, including the Dialysis Outcomes and Practice Patterns Study (DOPPS) [<xref ref-type="bibr" rid="R4">4</xref>], and the United States Renal Data System Dialysis Morbidity and Mortality Wave 2 study [<xref ref-type="bibr" rid="R5 R6">5,6</xref>] have provided important insights into the characteristics and likely prognosis of haemodialysis patients. A number of prospective epidemiological studies from several European countries have also described the incident haemodialysis population [<xref ref-type="bibr" rid="R7 R8 R9 R10 R11 R12 R13 R14 R15">7&#x02013;15</xref>], which can help to assess the influence of a multitude of risk factors on the increased mortality among these patients. In this regard, the ANSWER study is currently underway in a large incident haemodialysis population in Spain.</p><p>The primary objective of the ANSWER study is to determine and quantify the risk factors influencing cardiovascular morbidity and mortality in incident haemodialysis patients in Spain. In addition, the study also aims to provide information on the baseline characteristics of the incident haemodialysis population; in this paper, we report these data and make comparisons with other incident and prevalent populations reported in the literature.</p></sec><sec id="S2"><title>Subjects and methods</title><p>ANSWER is a multicentre, prospective, observational cohort study in incident haemodialysis patients all over Spain. Most dialysis facilities from Spain (<italic>n</italic> = 235) were invited to participate in the study, of which 147 (62.5%) centres agreed to participate. The local ethics committees approved the study and all patients enrolled in the study provided informed consent.</p><sec id="S2-1"><title>Patients</title><p>All incident haemodialysis patients (i.e. patients starting chronic haemodialysis treatment, who had received haemodialysis for &#x02264;30 days) aged &#x02265;18 years were eligible for inclusion in the study. Patients were excluded if they had undergone renal replacement therapy previously, were already receiving haemodialysis (&#x02265;30 days) or peritoneal dialysis, or had received a kidney transplant.</p><p>Following initiation of the study at each site in October 2003, patients were consecutively enrolled as they started haemodialysis treatment. Enrolment was stratified by region according to the incidence of haemodialysis in a reference population [<xref ref-type="bibr" rid="R16">16</xref>], in order to obtain a sample in which all Spanish regions would be represented in the same proportion as in the target population.</p></sec><sec id="S2-2"><title>Patient assessments</title><p>Sociodemographic, clinical, laboratory (maximum 30 days before start of haemodialysis) and health care (concomitant drug therapy and haemodialysis characteristics) variables were recorded at baseline (within first 30 days of haemodialysis) and assessed at regular intervals during the study period, with all the study patients followed up for at least 2 years.</p><p>Variables recorded at baseline included waist measurement, smoking status (active smoker, non-smoker, ex-smoker), alcohol consumption (grams of alcohol [<xref ref-type="bibr" rid="R17">17</xref>]), employment status and education. The clinical variables assessed included history of renal failure and various comorbidities: diabetes, dyslipidaemia [cholesterol &#x0003e;220 mg/dl or low-density cholesterol (LDL-C) &#x0003e;100 mg/dl or treatment with statins], hypertension [systolic blood pressure (SBP) &#x02265;140 mmHg or diastolic blood pressure (DBP) &#x02265;90 mmHg or treatment with antihypertensives], parathyroidectomy, malnutrition (physician's subjective assessment) and cardiovascular disease (heart failure, left ventricular hypertrophy, cardiac arrhythmia, ischaemic heart disease, cerebrovascular disease, peripheral vascular disease and any other diseases of the circulatory system). The Charlson age-comorbidity index [<xref ref-type="bibr" rid="R18 R19">18,19</xref>], performance status [Karnofsky score (KS)] and health<bold>-</bold>related quality of life (QoL) assessed with the Medical Outcome Survey Short Form 36 (SF-36) questionnaire [<xref ref-type="bibr" rid="R20">20</xref>], previously validated for the Spanish population [<xref ref-type="bibr" rid="R21">21</xref>], were also recorded.</p><p>Parameters describing the patients&#x02019; initial haemodialysis experience (first month after starting) were also obtained. Dialysis intolerance was defined as hypotension recorded at &#x0003e;50% of dialyses performed during the past month. The urea reduction ratio (URR) and Kt/V were calculated for each patient according to a standard formula (second-generation Daugirdas formula for eKt/V [<xref ref-type="bibr" rid="R22">22</xref>]). Glomerular filtration rate (GFR) was estimated according to the MDRD equation [<xref ref-type="bibr" rid="R23">23</xref>].</p><p>Bone mineral markers [intact parathyroid hormone (iPTH), phosphorus, total calcium and calcium&#x02013;phosphorus product (Ca &#x000d7; P)] were assessed according to the Kidney Disease Outcomes Quality Initiative (K/DOQI) target ranges [<xref ref-type="bibr" rid="R24">24</xref>]. Anaemia markers (haemoglobin, haematocrit, ferritin and saturated transferrin) were assessed according to the European Best Practice Guidelines (EBPG) [<xref ref-type="bibr" rid="R25">25</xref>].</p></sec><sec id="S2-3"><title>Statistical analysis</title><p>Summary statistics were calculated for continuous and categorical endpoints. Differences between subgroups were assessed using chi-square tests for categorical variables and Student's <italic>t</italic>-test or the Mann&#x02013;Whitney <italic>U</italic>-test for continuous variables (according to normality). The Bonferroni method [<xref ref-type="bibr" rid="R26">26</xref>] was applied for adjusting the significance level in these analyses. Differences were considered significant at <italic>P</italic> &#x0003c; 0.00022 (0.05/228). Differences between means and odds ratios with respect to the reference subgroup, together with their 95% confidence interval, are displayed only for the variables with significant results. The calculations were performed using SPSS&#x000ae; 14.0.</p></sec></sec><sec sec-type="results" id="S3"><title>Results</title><sec id="S3-1"><title>Sociodemographic characteristics and aetiology of kidney disease</title><p>A total of 2406 incident patients undergoing dialysis were enrolled from 147 hospital nephrology services and associated haemodialysis centres throughout Spain between 1 October 2003 and 30 September 2004. Sixty-five patients were excluded from analysis, as they did not meet the inclusion criteria. The resulting sample, 2341 patients, accounts for &#x0223c;58% of the total incident patients during the study period (according to the 2003 and 2004 estimates of the incidence of haemodialysis in Spain of the National Registry [<xref ref-type="bibr" rid="R27 R28">27,28</xref>]).</p><p>Table <xref ref-type="table" rid="T1">1</xref> summarizes the patient demographics and baseline characteristics. Most patients were elderly (29% over 75 years), male (63%) and overweight [59% had body mass index (BMI) &#x0003e;25 kg/m<sup>2</sup>]. The education level was low (38% had no primary education). The most common reason for renal failure was diabetic nephropathy (26%), and 27% of patients had been followed up by a nephrologist for &#x0003c;6 months prior to the onset of haemodialysis (24% in the subgroup with diabetic nephropathy and 26% in the subgroup with vascular nephropathy). The prevalence of hepatitis C virus positive patients was 5.4%.</p><table-wrap id="T1" position="float"><label>Table&#x000a0;1</label><caption><p>Baseline sociodemographic, clinical and haemodialysis characteristics of the study population</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Mean (SD) or <italic>N</italic> (%)</th><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Mean (SD) or <italic>N</italic> (%)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Mean age (years) (SD) (<italic>n</italic> = 2336)</td><td rowspan="1" colspan="1">65.2 (14.5)</td><td rowspan="1" colspan="1">Hypertension (<italic>n</italic> = 2283)</td><td rowspan="1" colspan="1">1975 (86%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;18&#x02013;44</td><td rowspan="1" colspan="1">258 (11%)</td><td rowspan="1" colspan="1">Diagnosed &#x0003c;1 year before<sup>a</sup> (<italic>n</italic> = 1174)</td><td rowspan="1" colspan="1">152 (13%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;45&#x02013;64</td><td rowspan="1" colspan="1">663 (28%)</td><td rowspan="1" colspan="1">Previous cardiovascular disease<sup>b</sup> (<italic>n</italic> = 2341)</td><td rowspan="1" colspan="1">1038 (44%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;65&#x02013;74</td><td rowspan="1" colspan="1">744 (32%)</td><td rowspan="1" colspan="1">Ischaemic CV Disease</td><td rowspan="1" colspan="1">701 (30%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02265;75</td><td rowspan="1" colspan="1">671 (29%)</td><td rowspan="1" colspan="1">Ischaemic heart disease</td><td rowspan="1" colspan="1">355 (15%)</td></tr><tr><td rowspan="1" colspan="1">Gender (<italic>n</italic> = 2341)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Peripheral vascular disease</td><td rowspan="1" colspan="1">272 (12%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Male</td><td rowspan="1" colspan="1">1470 (63%)</td><td rowspan="1" colspan="1">Cerebrovascular disease</td><td rowspan="1" colspan="1">263 (11%)</td></tr><tr><td rowspan="1" colspan="1">Race (<italic>n</italic> = 2323)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Heart failure</td><td rowspan="1" colspan="1">401 (17%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Europid</td><td rowspan="1" colspan="1">2275 (98%)</td><td rowspan="1" colspan="1">Cardiac arrhythmia</td><td rowspan="1" colspan="1">248 (11%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Other</td><td rowspan="1" colspan="1">48 (2%)</td><td rowspan="1" colspan="1">Other diseases of the circulatory system</td><td rowspan="1" colspan="1">141 (6%)</td></tr><tr><td rowspan="1" colspan="1">Mean BMI (kg/m<sup>2</sup>) (SD) (<italic>n</italic> = 2050)</td><td rowspan="1" colspan="1">26.6 (5.3)</td><td rowspan="1" colspan="1">Left ventricular hypertrophy (<italic>n</italic> = 2341)</td><td rowspan="1" colspan="1">374 (16%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;BMI &#x0003c;20 kg/m<sup>2</sup></td><td rowspan="1" colspan="1">146 (7%)</td><td rowspan="1" colspan="1">Dyslipidaemia<sup>c</sup> (<italic>n</italic> = 2261)</td><td rowspan="1" colspan="1">973 (43%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;20&#x02264;BMI&#x0003c;25 kg/m<sup>2</sup></td><td rowspan="1" colspan="1">701 (34%)</td><td rowspan="1" colspan="1">Diagnosed &#x0003c;1 year before<sup>a</sup> (<italic>n</italic> = 514)</td><td rowspan="1" colspan="1">108 (21%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;25&#x02264;BMI&#x0003c;30 kg/m<sup>2</sup> (overweight)</td><td rowspan="1" colspan="1">787 (39%)</td><td rowspan="1" colspan="1">Diabetes mellitus (<italic>n</italic> = 2285)</td><td rowspan="1" colspan="1">823 (36%)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Diagnosed &#x0003c;1 year before<sup>a</sup> (<italic>n</italic> = 466)</td><td rowspan="1" colspan="1">19 (4%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;BMI &#x02265;30 kg/m<sup>2</sup> (obesity)</td><td rowspan="1" colspan="1">416 (20%)</td><td rowspan="1" colspan="1">Malnutrition (<italic>n</italic> = 2246)</td><td rowspan="1" colspan="1">251 (11%)</td></tr><tr><td rowspan="1" colspan="1">Mean WC in males (cm) (SD) (<italic>n</italic> = 424)</td><td rowspan="1" colspan="1">96.5 (17.2)</td><td rowspan="1" colspan="1">Parathyroidectomy (<italic>n</italic> = 2266)</td><td rowspan="1" colspan="1">15 (0.7%)</td></tr><tr><td rowspan="1" colspan="1">Mean WC in females (cm) (SD) (<italic>n</italic> = 253)</td><td rowspan="1" colspan="1">93.6 (16.9)</td><td rowspan="1" colspan="1">Solid or non-solid tumour (<italic>n</italic> = 1992)</td><td rowspan="1" colspan="1">223 (11%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Abd.ob. males (WC &#x02265; 102 cm)</td><td rowspan="1" colspan="1">144 (34%)</td><td rowspan="1" colspan="1">Median Karnofsky score, (P25&#x02013;P75)<sup>d</sup> (<italic>n</italic> = 2160)</td><td rowspan="1" colspan="1">80 (60&#x02013;80)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Abd.ob. females (WC &#x02265; 88 cm)</td><td rowspan="1" colspan="1">167 (66%)</td><td rowspan="1" colspan="1">&#x02003;&#x0003c;50</td><td rowspan="1" colspan="1">68 (3%)</td></tr><tr><td rowspan="1" colspan="1">Reasons for renal failure (<italic>n</italic> = 2280)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02003;50&#x02013;70</td><td rowspan="1" colspan="1">861 (40%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Diabetic nephropathy</td><td rowspan="1" colspan="1">596 (26%)</td><td rowspan="1" colspan="1">&#x02003;80&#x02013;100</td><td rowspan="1" colspan="1">1231 (57%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Reno-vascular and hypertensive renal &#x02003;&#x02003;disease</td><td rowspan="1" colspan="1">383 (17%)</td><td rowspan="1" colspan="1">Mean of Charlson score (SD)<sup>e</sup> (<italic>n</italic> = 2249)</td><td rowspan="1" colspan="1">6.2 (2.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Glomerulonephritis</td><td rowspan="1" colspan="1">260 (11%)</td><td rowspan="1" colspan="1">&#x02003;2&#x02013;6</td><td rowspan="1" colspan="1">1223 (55%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Polycystic kidney disease</td><td rowspan="1" colspan="1">166 (7%)</td><td rowspan="1" colspan="1">&#x02003;7&#x02013;8</td><td rowspan="1" colspan="1">648 (29%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Chronic pyelonephritis</td><td rowspan="1" colspan="1">140 (6%)</td><td rowspan="1" colspan="1">&#x02003;&#x02265;9</td><td rowspan="1" colspan="1">378 (16%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Systemic</td><td rowspan="1" colspan="1">90 (4%)</td><td rowspan="1" colspan="1">SF-36<sup>f</sup> (<italic>n</italic> = 847)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Hereditary</td><td rowspan="1" colspan="1">15 (1%)</td><td rowspan="1" colspan="1">Mean PCS (SD)</td><td rowspan="1" colspan="1">36.4 (9.9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Unknown aetiology</td><td rowspan="1" colspan="1">482 (21%)</td><td rowspan="1" colspan="1">Mean MCS (SD)</td><td rowspan="1" colspan="1">39.9 (13.0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Other</td><td rowspan="1" colspan="1">148 (7%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Mean duration of predialysis nephrologist &#x02003;&#x02003;follow-up (months) (SD) (<italic>n</italic> = 2212)</td><td rowspan="1" colspan="1">36.8 (34.9)</td><td rowspan="1" colspan="1">Haemodialysis technique (<italic>n</italic> = 2087)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02264;6 months</td><td rowspan="1" colspan="1">610 (27%)</td><td rowspan="1" colspan="1">Conventional</td><td rowspan="1" colspan="1">2047 (98%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;7&#x02013;12 months</td><td rowspan="1" colspan="1">216 (10%)</td><td rowspan="1" colspan="1">Special<sup>g</sup></td><td rowspan="1" colspan="1">40 (2%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x0003e;12 months</td><td rowspan="1" colspan="1">1386 (63%)</td><td rowspan="1" colspan="1">HD frequency, session/week (<italic>n</italic> = 2109)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Tobacco use (<italic>n</italic> = 2187)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3 session/week</td><td rowspan="1" colspan="1">2053 (97%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Non-smoker</td><td rowspan="1" colspan="1">756 (35%)</td><td rowspan="1" colspan="1">Other</td><td rowspan="1" colspan="1">56 (3%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Former smoker</td><td rowspan="1" colspan="1">1181 (54%)</td><td rowspan="1" colspan="1">Mean HD duration (hours/session) (SD) (<italic>n</italic> = 2091)</td><td rowspan="1" colspan="1">3.6 (0.7)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Current smoker</td><td rowspan="1" colspan="1">250 (11%)</td><td rowspan="1" colspan="1">Membrane type (<italic>n</italic> = 2085)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Alcohol consumption (<italic>n</italic> = 2159)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Low-flux</td><td rowspan="1" colspan="1">1158 (56%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;None</td><td rowspan="1" colspan="1">1908 (88%)</td><td rowspan="1" colspan="1">High-flux</td><td rowspan="1" colspan="1">927 (44%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Any</td><td rowspan="1" colspan="1">251 (12%)</td><td rowspan="1" colspan="1">Heparin (<italic>n</italic> = 1695)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Employment status (<italic>n</italic> = 2151)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Low molecular weight</td><td rowspan="1" colspan="1">804 (47%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Retired</td><td rowspan="1" colspan="1">1328 (62%)</td><td rowspan="1" colspan="1">Standard</td><td rowspan="1" colspan="1">891 (53%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Disabled</td><td rowspan="1" colspan="1">308 (14%)</td><td rowspan="1" colspan="1">Vascular access (<italic>n</italic> = 2124)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Active</td><td rowspan="1" colspan="1">271 (13%)</td><td rowspan="1" colspan="1">Permanent catheter</td><td rowspan="1" colspan="1">347 (16%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Unemployed</td><td rowspan="1" colspan="1">244 (11%)</td><td rowspan="1" colspan="1">Temporary catheter</td><td rowspan="1" colspan="1">642 (30%)</td></tr><tr><td rowspan="1" colspan="1">Educational status (<italic>n</italic> = 2063)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">IAVF-distal</td><td rowspan="1" colspan="1">644 (31%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Cannot read or write</td><td rowspan="1" colspan="1">138 (7%)</td><td rowspan="1" colspan="1">IAVF-proximal</td><td rowspan="1" colspan="1">441 (21%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Can read or write</td><td rowspan="1" colspan="1">643 (31%)</td><td rowspan="1" colspan="1">PTFE graft</td><td rowspan="1" colspan="1">50 (2%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Primary education</td><td rowspan="1" colspan="1">903 (44%)</td><td rowspan="1" colspan="1">Blood pressure before HD session</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Secondary education</td><td rowspan="1" colspan="1">266 (13%)</td><td rowspan="1" colspan="1">Mean SBP (mmHg) (SD) (<italic>n</italic> = 1457)</td><td rowspan="1" colspan="1">140.5 (21.7)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;University studies</td><td rowspan="1" colspan="1">113 (5%)</td><td rowspan="1" colspan="1">Mean DBP (mmHg) (SD) (<italic>n</italic> = 1458)</td><td rowspan="1" colspan="1">75.4 (12.2)</td></tr><tr><td rowspan="1" colspan="1">Hepatitis B (+) (<italic>n</italic> = 2306)</td><td rowspan="1" colspan="1">25 (1%)</td><td rowspan="1" colspan="1">Mean interdialysis weight gain (kg) (SD) (<italic>n</italic> = 1499)</td><td rowspan="1" colspan="1">1.07 (0.95)</td></tr><tr><td rowspan="1" colspan="1">Hepatitis C (+) (<italic>n</italic> = 2296)</td><td rowspan="1" colspan="1">119 (5%)</td><td rowspan="1" colspan="1">Mean urea reduction ratio (%) (SD) (<italic>n</italic> = 1079)</td><td rowspan="1" colspan="1">62.3 (12.2)</td></tr><tr><td rowspan="1" colspan="1">HIV (+) (<italic>n</italic> = 2290)</td><td rowspan="1" colspan="1">16 (0.7%)</td><td rowspan="1" colspan="1">Mean (eKt/V) (SD) (<italic>n</italic> = 1044)</td><td rowspan="1" colspan="1">1.17 (0.53)</td></tr></tbody></table><table-wrap-foot><fn id="T1TFN1"><p>Baseline demographic characteristics are described for 2341 incident haemodialysis patients recruited from 147 nephrology centres in Spain. Values are expressed as number of patients and percentages on the valid sample indicated in parentheses for each variable.</p></fn><fn id="T1TFN2"><p><italic>N</italic> = number of patients; SD = standard deviation; p25 = percentile 25; p75 = percentile 75; WC = waist circumference; Abd. ob. = abdominal obesity; IAVF = internal arteriovenous fistula; PTFE = polytetrafluoroethylene; SBP = systolic blood pressure; DBP = diastolic blood pressure; CV = cardiovascular; HD = haemodialysis.</p></fn><fn id="T1TFN3"><p><sup>a</sup>Percentage calculated for the hypertensive, dyslipidaemic or diabetic patients with information available, respectively.</p></fn><fn id="T1TFN4"><p><sup>b</sup>Excluding left ventricular hypertrophy.</p></fn><fn id="T1TFN5"><p><sup>c</sup>Cholesterol &#x0003e;220 mg/dl or LDL-C &#x0003e;100 mg/dl or treatment with statins.</p></fn><fn id="T1TFN6"><p><sup>d</sup>On a scale 0&#x02013;100, with 100 = the normal ability to carry out daily activities.</p></fn><fn id="T1TFN7"><p><sup>e</sup>Age adjusted; on a scale 0&#x02013;37, with 37 = the highest comorbidity.</p></fn><fn id="T1TFN8"><p><sup>f</sup>SF-36 Physical Component Summary Scale (PCS) and Mental Component Summary Scale (MCS) are calculated based on <italic>T</italic> transformations, so that the mean score of the general Spanish population is 50 and the standard deviation is 10 (a value between 45 and 55 is considered &#x02018;normal&#x02019;, between 40 and 45 &#x02018;somewhat worse&#x02019; and &#x0003c;40 &#x02018;worse&#x02019; than 70% of the general population).</p></fn><fn id="T1TFN9"><p><sup>g</sup>Short daily haemodialysis or nocturnal haemodialysis.</p></fn></table-wrap-foot></table-wrap></sec><sec id="S3-2"><title>Comorbidities, functional status, medications and quality of life</title><p>Comorbidities were common, particularly hypertension (86%), with almost all hypertensive patients being non-controlled (89% with SPB &#x02265;140 mmHg or DBP &#x02265;90 mmHg), despite most of them receiving antihypertensive treatment (80%). There was also a high frequency of previous cardiovascular disease (44%) and dyslipidaemia (43%) (Table <xref ref-type="table" rid="T1">1</xref>). The prevalence of diabetes mellitus was 10% higher than that of diabetic nephropathy. Approximately 1 in 10 patients had developed a tumour.</p><p>As expected, the use of concomitant medications reflects the comorbidities in this population (Table <xref ref-type="table" rid="T2">2</xref>). Half of the patients were treated with iron supplements either before (47%) or after (53%) the initiation of haemodialysis. Most patients were receiving or were starting treatment with erythropoiesis-stimulating agents (ESA, 80%) and phosphate binders (71%). Of the patients on ESAs, 52% were treated prior to dialysis initiation (62% in the subgroup with &#x0003e;6 months of predialysis nephrological care versus 38% in the &#x02264;6 months group, <italic>P</italic> &#x0003c; 0.0001) and 48% began ESA treatment at the time of dialysis initiation. The use of beta-blockers was lower than expected in view of the comorbidities (24% of total sample, 16% as antihypertensive treatment and 8% as cardiovascular therapy).</p><table-wrap id="T2" position="float"><label>Table&#x000a0;2</label><caption><p>Use of concomitant medications at haemodialysis initiation</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Valid <italic>N</italic></th><th align="left" rowspan="1" colspan="1"><italic>N</italic> (%)</th><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Valid <italic>N</italic></th><th align="left" rowspan="1" colspan="1"><italic>N</italic> (%)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Erythropoiesis-stimulating agents<sup>a</sup></td><td rowspan="1" colspan="1">2267</td><td rowspan="1" colspan="1">1814 (80%)</td><td rowspan="1" colspan="1">Antihypertensives</td><td rowspan="1" colspan="1">2269</td><td rowspan="1" colspan="1">1815 (80%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Rhu-Epo</td><td rowspan="1" colspan="1">1814</td><td rowspan="1" colspan="1">996 (54%)</td><td rowspan="1" colspan="1">&#x02003;Calcium antagonists</td><td rowspan="1" colspan="1">1815</td><td rowspan="1" colspan="1">1101 (61%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Darbepoetin alfa</td><td rowspan="1" colspan="1">1814</td><td rowspan="1" colspan="1">818 (45%)</td><td rowspan="1" colspan="1">&#x02003;&#x003b1;-blockers</td><td rowspan="1" colspan="1">1815</td><td rowspan="1" colspan="1">563 (31%)</td></tr><tr><td rowspan="1" colspan="1">Iron<sup>b</sup></td><td rowspan="1" colspan="1">2254</td><td rowspan="1" colspan="1">1127 (50%)</td><td rowspan="1" colspan="1">&#x02003;ACE inhibitors</td><td rowspan="1" colspan="1">1815</td><td rowspan="1" colspan="1">554 (31%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic>Intravenous</italic><sup>c</sup></td><td rowspan="1" colspan="1">1106</td><td rowspan="1" colspan="1">774 (70%)</td><td rowspan="1" colspan="1">&#x02003;ARA II</td><td rowspan="1" colspan="1">1815</td><td rowspan="1" colspan="1">543 (30%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic>Oral</italic><sup>c</sup></td><td rowspan="1" colspan="1">1106</td><td rowspan="1" colspan="1">332 (30%)</td><td rowspan="1" colspan="1">&#x02003;&#x003b2;-blockers</td><td rowspan="1" colspan="1">1815</td><td rowspan="1" colspan="1">352 (19%)</td></tr><tr><td rowspan="1" colspan="1">Phosphate binders</td><td rowspan="1" colspan="1">2232</td><td rowspan="1" colspan="1">1585 (71%)</td><td rowspan="1" colspan="1">&#x02003;Diuretics</td><td rowspan="1" colspan="1">1815</td><td rowspan="1" colspan="1">342 (19%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;CO<sub>3</sub>Ca</td><td rowspan="1" colspan="1">1585</td><td rowspan="1" colspan="1">1091 (69%)</td><td rowspan="1" colspan="1">&#x02003;&#x003b1; /&#x003b2;-blockers</td><td rowspan="1" colspan="1">1815</td><td rowspan="1" colspan="1">130 (7%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Sevelamer</td><td rowspan="1" colspan="1">1585</td><td rowspan="1" colspan="1">298 (19%)</td><td rowspan="1" colspan="1">&#x02003;Other</td><td rowspan="1" colspan="1">1815</td><td rowspan="1" colspan="1">53 (3%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Calcium acetate</td><td rowspan="1" colspan="1">1585</td><td rowspan="1" colspan="1">269 (17%)</td><td rowspan="1" colspan="1">Cardiovascular drugs</td><td rowspan="1" colspan="1">2250</td><td rowspan="1" colspan="1">990 (44%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Al(OH)<sub>3</sub></td><td rowspan="1" colspan="1">1585</td><td rowspan="1" colspan="1">121 (8%)</td><td rowspan="1" colspan="1">&#x02003;Nitrates</td><td rowspan="1" colspan="1">990</td><td rowspan="1" colspan="1">249 (25%)</td></tr><tr><td rowspan="1" colspan="1">Vitamin D analogues/metabolites</td><td rowspan="1" colspan="1">2216</td><td rowspan="1" colspan="1">687 (31%)</td><td rowspan="1" colspan="1">&#x02003;&#x003b2;-blockers</td><td rowspan="1" colspan="1">990</td><td rowspan="1" colspan="1">184 (19%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Calcitriol</td><td rowspan="1" colspan="1">687</td><td rowspan="1" colspan="1">666 (97%)</td><td rowspan="1" colspan="1">&#x02003;Antiarrhythmic drugs</td><td rowspan="1" colspan="1">990</td><td rowspan="1" colspan="1">101 (10%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Other</td><td rowspan="1" colspan="1">687</td><td rowspan="1" colspan="1">17 (2%)</td><td rowspan="1" colspan="1">&#x02003;Digital</td><td rowspan="1" colspan="1">990</td><td rowspan="1" colspan="1">78 (8%)</td></tr><tr><td rowspan="1" colspan="1">Vitamins</td><td rowspan="1" colspan="1">2267</td><td rowspan="1" colspan="1">476 (21%)</td><td rowspan="1" colspan="1">&#x02003;Other</td><td rowspan="1" colspan="1">990</td><td rowspan="1" colspan="1">378 (38%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Folic acid</td><td rowspan="1" colspan="1">476</td><td rowspan="1" colspan="1">421 (88%)</td><td rowspan="1" colspan="1">Antithrombotics</td><td rowspan="1" colspan="1">2259</td><td rowspan="1" colspan="1">655 (29%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Vitamin C</td><td rowspan="1" colspan="1">476</td><td rowspan="1" colspan="1">198 (42%)</td><td rowspan="1" colspan="1">Anticoagulants</td><td rowspan="1" colspan="1">2112</td><td rowspan="1" colspan="1">169 (8%)</td></tr><tr><td rowspan="1" colspan="1">Hypoglycaemics</td><td rowspan="1" colspan="1">2236</td><td rowspan="1" colspan="1">626 (28%)</td><td rowspan="1" colspan="1">Hypolipidaemics</td><td rowspan="1" colspan="1">2228</td><td rowspan="1" colspan="1">713 (32%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Insulin</td><td rowspan="1" colspan="1">626</td><td rowspan="1" colspan="1">540 (86%)</td><td rowspan="1" colspan="1">&#x02003;Statins</td><td rowspan="1" colspan="1">713</td><td rowspan="1" colspan="1">676 (95%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Oral antidiabetics</td><td rowspan="1" colspan="1">626</td><td rowspan="1" colspan="1">86 (14%)</td><td rowspan="1" colspan="1">&#x02003;Fibrates</td><td rowspan="1" colspan="1">713</td><td rowspan="1" colspan="1">41 (6%)</td></tr></tbody></table><table-wrap-foot><fn id="T2TFN1"><p>Values are expressed as percentages on patients receiving the corresponding therapeutic group, except for major categories, calculated on total valid sample. The valid <italic>N</italic> for each percentage is shown in the second and fifth columns. Total sample size, 2341.</p></fn><fn id="T2TFN2"><p><italic>N</italic> = number of patients; ACE = angiotensin-converting enzyme; ARAII = angiotensin II receptor antagonist.</p></fn><fn id="T2TFN3"><p><sup>a</sup>Among patients on ESA, 52% were treated previously to HD initiation.</p></fn><fn id="T2TFN4"><p><sup>b</sup>Among patients on iron, 47% were treated previously to HD initiation.</p></fn><fn id="T2TFN5"><p><sup>c</sup>Percentages calculated for the subgroup of patients receiving iron with information available.</p></fn></table-wrap-foot></table-wrap><p>The presence of comorbidities [mean of Charlson Index of 6.2 (SD 2.4)] resulted in a severely decreased quality of life when compared with the general Spanish population (Table <xref ref-type="table" rid="T1">1</xref>). Over half of the patients (57%) had a Karnofsky score between 80 and 100. Younger patients had a better functional status [mean KS of 82 (SD 14) for patients &#x0003c;65 years] than the older patients [71 (16) for patients &#x02265;65 years, <italic>P</italic> &#x0003c; 0.0005].</p></sec><sec id="S3-3"><title>Blood chemistry</title><p>Table <xref ref-type="table" rid="T3">3</xref> summarizes the patients&#x02019; baseline blood chemistry values. A high proportion of diabetic patients had uncontrolled glycaemia (48% &#x0003e;126 mg/dl, 34% with HbA1c &#x0003e;7%), whereas LDL-C was mostly within the normal range and high-density lipoprotein (HDL)-cholesterol was below the normal range in one-third of cases. The nutritional status of the patients was quite poor (43% had albumin levels &#x0003c;3.5 g/dl) and the inflammation status was highly variable (SD 6.2 mg/dl for the C-reactive protein). The mean GFR prior to dialysis onset was 7.6 (SD 2.8) ml/min/1.73 m<sup>2</sup> and the mean 24-h diuresis was 1602 (SD 920) ml.</p><table-wrap id="T3" position="float"><label>Table&#x000a0;3</label><caption><p>Blood chemistry at baseline</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><italic>N</italic></th><th align="left" rowspan="1" colspan="1">Mean (SD)</th><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><italic>N</italic> patients (%)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Glucose (mg/dl)</td><td rowspan="1" colspan="1">2138</td><td rowspan="1" colspan="1">113 (46)</td><td rowspan="1" colspan="1">&#x02265;126 mg/dl<sup>a</sup></td><td rowspan="1" colspan="1">367 (48%)</td></tr><tr><td rowspan="1" colspan="1">HbA1c (%)</td><td rowspan="1" colspan="1">568</td><td rowspan="1" colspan="1">6.2 (1.5)</td><td rowspan="1" colspan="1">&#x0003e;7%<sup>a</sup></td><td rowspan="1" colspan="1">124 (34%)</td></tr><tr><td rowspan="1" colspan="1">Cholesterol (mg/dl)</td><td rowspan="1" colspan="1">1961</td><td rowspan="1" colspan="1">171 (46)</td><td rowspan="1" colspan="1">&#x0003e;200 mg/dl</td><td rowspan="1" colspan="1">451 (23%)</td></tr><tr><td rowspan="1" colspan="1">Cholesterol HDL (mg/dl)</td><td rowspan="1" colspan="1">1269</td><td rowspan="1" colspan="1">47 (18)</td><td rowspan="1" colspan="1">&#x0003c;40 mg/dl</td><td rowspan="1" colspan="1">457 (36%)</td></tr><tr><td rowspan="1" colspan="1">Cholesterol LDL (mg/dl)</td><td rowspan="1" colspan="1">1162</td><td rowspan="1" colspan="1">102 (37)</td><td rowspan="1" colspan="1">&#x0003e;160 mg/dl</td><td rowspan="1" colspan="1">93 (8%)</td></tr><tr><td rowspan="1" colspan="1">Triglycerides (mg/dl)</td><td rowspan="1" colspan="1">1914</td><td rowspan="1" colspan="1">134 (70)</td><td rowspan="1" colspan="1">&#x0003e;200 mg/dl</td><td rowspan="1" colspan="1">268 (14%)</td></tr><tr><td rowspan="1" colspan="1">Albumin (g/dl)</td><td rowspan="1" colspan="1">1796</td><td rowspan="1" colspan="1">3.5 (0.6)</td><td rowspan="1" colspan="1">&#x0003c;3.5 g/dl</td><td rowspan="1" colspan="1">771 (43%)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3.5&#x02013;4.0 g/dl</td><td rowspan="1" colspan="1">694 (39%)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x0003e;4.0 g/dl</td><td rowspan="1" colspan="1">331 (18%)</td></tr><tr><td rowspan="1" colspan="1">Creatinine (mg/dl)</td><td rowspan="1" colspan="1">2175</td><td rowspan="1" colspan="1">6.9 (2.5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Serum urea (mg/dl)</td><td rowspan="1" colspan="1">2043</td><td rowspan="1" colspan="1">184 (69)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">High-sensitivity C-reactive</td><td rowspan="1" colspan="1">313</td><td rowspan="1" colspan="1">5.3 (6.2)/3 (0.9, 7)<sup>b</sup></td><td rowspan="1" colspan="1">&#x0003e;7.5 mg/dl</td><td rowspan="1" colspan="1">72 (23%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;protein (mg/dl)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Vitamin B12 (pg/ml)</td><td rowspan="1" colspan="1">583</td><td rowspan="1" colspan="1">512 (204)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Lipoprotein A (mg/dl)</td><td rowspan="1" colspan="1">321</td><td rowspan="1" colspan="1">56 (47)</td><td rowspan="1" colspan="1">&#x0003e;30 mg/dl</td><td rowspan="1" colspan="1">184 (58%)</td></tr><tr><td rowspan="1" colspan="1">Homocysteine (&#x003bc;mol/l)</td><td rowspan="1" colspan="1">361</td><td rowspan="1" colspan="1">25.9 (13)</td><td rowspan="1" colspan="1">&#x0003e;18 &#x003bc;mol/l</td><td rowspan="1" colspan="1">253 (70%)</td></tr><tr><td rowspan="1" colspan="1">Fibrinogen (g/l)</td><td rowspan="1" colspan="1">533</td><td rowspan="1" colspan="1">5.3 (1.9)</td><td rowspan="1" colspan="1">&#x0003e;4.5 g/l</td><td rowspan="1" colspan="1">331 (62%)</td></tr><tr><td rowspan="1" colspan="1">Potassium (mmol/l)</td><td rowspan="1" colspan="1">2177</td><td rowspan="1" colspan="1">4.9 (0.8)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Magnesium (mg/dl)</td><td rowspan="1" colspan="1">627</td><td rowspan="1" colspan="1">2.2 (0.5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">ALT (U/l)</td><td rowspan="1" colspan="1">1957</td><td rowspan="1" colspan="1">21 (40)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">AST (U/l)</td><td rowspan="1" colspan="1">1929</td><td rowspan="1" colspan="1">20 (34)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Alkaline phosphatase (U/l)</td><td rowspan="1" colspan="1">1714</td><td rowspan="1" colspan="1">129 (92)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">GFR (ml/min/1.73 m<sup>2</sup>)</td><td rowspan="1" colspan="1">1559</td><td rowspan="1" colspan="1">7.6 (2.8)</td><td rowspan="1" colspan="1">&#x0003c;10 ml/min/1.73 m<sup>2</sup></td><td rowspan="1" colspan="1">1294 (83%)</td></tr><tr><td rowspan="1" colspan="1">24-h diuresis (ml)</td><td rowspan="1" colspan="1">1370</td><td rowspan="1" colspan="1">1602 (920)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="T3TFN1"><p>Percentages calculated on valid sample for each variable (indicated in the second column), unless otherwise specified.</p></fn><fn id="T3TFN2"><p><italic>N</italic> = sample size of the described variable; SD = standard deviation.</p></fn><fn id="T3TFN3"><p><sup>a</sup>% of diabetic patients with determination available (<italic>n</italic> = 765 for glucose, <italic>n</italic> = 360 for HbA1c).</p></fn><fn id="T3TFN4"><p><sup>b</sup>Median (P25, P75).</p></fn></table-wrap-foot></table-wrap></sec><sec id="S3-4"><title>Anaemia and mineral metabolism</title><p>A large proportion of patients were outside the EBPG targets for haematological parameters related to the management of anaemia (haemoglobin &#x0003c;11 g/dl in 59%). Ferritin and saturated transferrin levels were decreased in 31% and 39% of patients, respectively. Most patients were also outside the K/DOQI guideline target ranges for bone mineral markers (Table <xref ref-type="table" rid="T4">4</xref>). Overall, only 6.7% of the patients were within the four K/DOQI target ranges at the same time. The population means were also outside the K/DOQI guideline target ranges for iPTH and phosphorus, but not for total albumin-adjusted calcium or Ca &#x000d7; P, probably due to the large percentage of patients with low total calcium levels.</p><table-wrap id="T4" position="float"><label>Table&#x000a0;4</label><caption><p>Haematological and bone mineral markers parameters at baseline</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><italic>N</italic></th><th align="left" rowspan="1" colspan="1">Mean (SD)</th><th colspan="3" align="center" rowspan="1"><italic>N</italic> patients (%)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x0003c;11</td><td rowspan="1" colspan="1">&#x02265;11</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Haemoglobin (g/dl)</td><td rowspan="1" colspan="1">2198</td><td rowspan="1" colspan="1">10.6 (1.7)</td><td rowspan="1" colspan="1">1289 (59%)</td><td rowspan="1" colspan="1">909 (41%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x0003c;33</td><td rowspan="1" colspan="1">33&#x02013;36</td><td rowspan="1" colspan="1">&#x02265;37</td></tr><tr><td rowspan="1" colspan="1">Haematocrit (%)</td><td rowspan="1" colspan="1">2201</td><td rowspan="1" colspan="1">32.0 (5.2)</td><td rowspan="1" colspan="1">1244 (57%)</td><td rowspan="1" colspan="1">447 (20%)</td><td rowspan="1" colspan="1">510 (23%)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x0003c;100</td><td rowspan="1" colspan="1">100&#x02013;500</td><td rowspan="1" colspan="1">&#x0003e;500</td></tr><tr><td rowspan="1" colspan="1">Ferritin (ng/ml)</td><td rowspan="1" colspan="1">1718</td><td rowspan="1" colspan="1">236 (238)</td><td rowspan="1" colspan="1">529 (31%)</td><td rowspan="1" colspan="1">1015 (59%)</td><td rowspan="1" colspan="1">174 (10%)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x0003c;20</td><td rowspan="1" colspan="1">20&#x02013;40</td><td rowspan="1" colspan="1">41&#x02013;100</td></tr><tr><td rowspan="1" colspan="1">Saturated transferrin (%)</td><td rowspan="1" colspan="1">1219</td><td rowspan="1" colspan="1">25.3 (13.8)</td><td rowspan="1" colspan="1">479 (39%)</td><td rowspan="1" colspan="1">611 (50%)</td><td rowspan="1" colspan="1">129 (11%)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Low</td><td rowspan="1" colspan="1">Normal<sup>a</sup></td><td rowspan="1" colspan="1">High</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x0003c;150</td><td rowspan="1" colspan="1">150&#x02013;300</td><td rowspan="1" colspan="1">&#x0003e;300</td></tr><tr><td rowspan="1" colspan="1">iPTH (pg/ml)</td><td rowspan="1" colspan="1">1556</td><td rowspan="1" colspan="1">348 (259)</td><td rowspan="1" colspan="1">425 (27%)</td><td rowspan="1" colspan="1">468 (30%)</td><td rowspan="1" colspan="1">663 (43%)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x0003c;3.5</td><td rowspan="1" colspan="1">3.5&#x02013;5.5</td><td rowspan="1" colspan="1">&#x0003e;5.5</td></tr><tr><td rowspan="1" colspan="1">Phosphorus (mg/dl)</td><td rowspan="1" colspan="1">2109</td><td rowspan="1" colspan="1">5.6 (1.7)</td><td rowspan="1" colspan="1">129 (6%)</td><td rowspan="1" colspan="1">999 (47%)</td><td rowspan="1" colspan="1">981 (47%)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x0003c;8.4</td><td rowspan="1" colspan="1">8.4&#x02013;9.5</td><td rowspan="1" colspan="1">&#x0003e;9.5</td></tr><tr><td rowspan="1" colspan="1">Adjusted calcium (mg/dl)<sup>b</sup></td><td rowspan="1" colspan="1">1787</td><td rowspan="1" colspan="1">9.1 (1.0)</td><td rowspan="1" colspan="1">325 (18%)</td><td rowspan="1" colspan="1">846 (48%)</td><td rowspan="1" colspan="1">616 (34%)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">&#x02264;55</td><td rowspan="1" colspan="1">&#x0003e;55</td></tr><tr><td rowspan="1" colspan="1">Ca &#x000d7; P (mg<sup>2</sup>/dl<sup>2</sup>)</td><td rowspan="1" colspan="1">1759</td><td rowspan="1" colspan="1">51 (15)</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">1158 (66%)</td><td rowspan="1" colspan="1">601 (34%)</td></tr></tbody></table><table-wrap-foot><fn id="T4TFN1"><p>Percentages calculated on valid sample for each variable (indicated in the second column).</p></fn><fn id="T4TFN2"><p><italic>N</italic> = sample size; na = not applicable.</p></fn><fn id="T4TFN3"><p><sup>a</sup>&#x02018;Normal&#x02019; represents the K/DOQI guideline target range for bone mineral markers.</p></fn><fn id="T4TFN4"><p><sup>b</sup>Adjusted with the following formula: Adjusted Ca = calcium + 0.8 <sup>*</sup>(4-albumin).</p></fn></table-wrap-foot></table-wrap></sec><sec id="S3-5"><title>Baseline haemodialysis characteristics</title><p>Baseline haemodialysis variables are detailed in Table <xref ref-type="table" rid="T1">1</xref>. The majority of patients received three haemodialysis sessions per week with a mean of 3.6 h of dialysis per session. Similar proportions of patients had high-flux or low-flux membranes and similar proportions received low-molecular-weight or standard heparin. Vascular access in patients at the start of haemodialysis was achieved by using either catheter (46%) or arteriovenous fistula (AVF) (52%) and in a small proportion of patients using polytetrafluoroethylene AVF (2%).</p></sec><sec id="S3-6"><title>Characteristics of the patients with initial vascular access via a catheter</title><p>The patients with initial vascular access via a permanent catheter were older and had worse nutritional status, more comorbidities (higher Charlson index) and worse residual renal function (lower 24-h diuresis) than patients with a temporary catheter or an AVF (Table <xref ref-type="table" rid="T5">5</xref>). The subgroup with temporary catheters was characterized by greater use of low-molecular-weight heparin and a higher degree of anaemia, hypocalcaemia and hyperphosphataemia (Table <xref ref-type="table" rid="T5">5</xref>).</p><table-wrap id="T5" position="float"><label>Table&#x000a0;5</label><caption><p>Differences in clinical and sociodemographic characteristics of incident haemodialysis patients grouped by the type of initial vascular access (only those variables with significant differences with respect to AV fistula patients are displayed)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Permanent catheter (<italic>N</italic> = 347, 16%)</th><th align="left" rowspan="1" colspan="1">Temporary catheter (<italic>N</italic> = 642, 30%)</th><th align="left" rowspan="1" colspan="1">AV fistula<sup>a</sup>, reference (<italic>N</italic> = 1085, 52%)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value<sup>*</sup></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">4.5 (2.3; 5.6)</td><td rowspan="1" colspan="1">1.1 (&#x02212;0.4; 2.4)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Weight (kg)</td><td rowspan="1" colspan="1">&#x02212;4.4 (&#x02212;5.8; &#x02212;2.1)</td><td rowspan="1" colspan="1">&#x02212;2.22 (&#x02212;3.4; &#x02212;0.5)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.0002</td></tr><tr><td rowspan="1" colspan="1">Karnofsky score</td><td rowspan="1" colspan="1">&#x02212;10 (&#x02212;12; &#x02212;7.9)</td><td rowspan="1" colspan="1">&#x02212;7 (&#x02212;8.5; &#x02212;5.4)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Charlson index</td><td rowspan="1" colspan="1">1.2 (0.9; 1.4)</td><td rowspan="1" colspan="1">0.6 (0.3; 0.8)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">CKD aetiology = diabetic &#x02007;nephropathy</td><td rowspan="1" colspan="1">1.6 (1.2; 2.1)</td><td rowspan="1" colspan="1">1.5 (1.2; 1.9)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">CKD aetiology = &#x02007;glomerulonephritis</td><td rowspan="1" colspan="1">0.5 (0.3; 0.8)</td><td rowspan="1" colspan="1">0.7 (0.5; 1.0)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">CKD aetiology = polycystic &#x02007;kidney disease</td><td rowspan="1" colspan="1">0.3 (0.1; 0.5)</td><td rowspan="1" colspan="1">0.2 (0.1; 0.4)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">CKD aetiology = systemic</td><td rowspan="1" colspan="1">3 (1.6; 5.5)</td><td rowspan="1" colspan="1">2.6 (1.5; 4.4)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Employment status = retired</td><td rowspan="1" colspan="1">1.4 (1.0; 1.8)</td><td rowspan="1" colspan="1">1 (0.8; 1.3)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.0002</td></tr><tr><td rowspan="1" colspan="1">Haemodialysis duration &#x02007;(hours/session)</td><td rowspan="1" colspan="1">0.1 (0.01; 0.18)</td><td rowspan="1" colspan="1">0.2 (0.13; 0.26)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Low-molecular-weight &#x02007;heparin</td><td rowspan="1" colspan="1">0.8 (0.6; 1.1)</td><td rowspan="1" colspan="1">1.5 (1.2; 1.8)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Diabetes mellitus</td><td rowspan="1" colspan="1">1.6 (1.2; 2.0)</td><td rowspan="1" colspan="1">1.5 (1.2; 1.9)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Hypertension</td><td rowspan="1" colspan="1">0.4 (0.3; 0.6)</td><td rowspan="1" colspan="1">0.7 (0.5; 0.9)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Hypertension diagnosed &#x0003c;1 &#x02007;year before<sup>b</sup></td><td rowspan="1" colspan="1">1.6 (0.9; 2.7)</td><td rowspan="1" colspan="1">2.3 (1.5; 3.4)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.0002</td></tr><tr><td rowspan="1" colspan="1">Malnutrition</td><td rowspan="1" colspan="1">2.6 (1.8; 3.8)</td><td rowspan="1" colspan="1">1.6 (1.1; 2.2)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Albumin (g/dl)</td><td rowspan="1" colspan="1">&#x02212;0.4 (&#x02212;0.47; &#x02212;0.32)</td><td rowspan="1" colspan="1">&#x02212;0.4 (&#x02212;0.44; &#x02212;0.36.)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">C-reactive protein (mg/dl)</td><td rowspan="1" colspan="1">0.3 (&#x02212;2.2; 3.0)</td><td rowspan="1" colspan="1">3.3 (0.9; 5.8)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.0001</td></tr><tr><td rowspan="1" colspan="1">Triglycerides (mg/dl)</td><td rowspan="1" colspan="1">21 (8; 35)</td><td rowspan="1" colspan="1">10 (0; 20)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Creatinine (mg/dl)</td><td rowspan="1" colspan="1">0.1 (&#x02212;0.2; 0.4)</td><td rowspan="1" colspan="1">0.8 (0.5; 1.2)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Serum urea (mg/dl)</td><td rowspan="1" colspan="1">&#x02212;12 (&#x02212;21.5; &#x02212;2.4)</td><td rowspan="1" colspan="1">9 (1.6; 16.3)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">24-h diuresis (ml)</td><td rowspan="1" colspan="1">&#x02212;474 (&#x02212;285; &#x02212;663)</td><td rowspan="1" colspan="1">&#x02212;342 (&#x02212;181; 503)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Haemoglobin &#x0003c;11 g/dl</td><td rowspan="1" colspan="1">1.9 (1.5; 2.5)</td><td rowspan="1" colspan="1">2.6 (2.1; 3.2)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Ferritin &#x02265; 500 ng/ml</td><td rowspan="1" colspan="1">2 (1.3; 3.3)</td><td rowspan="1" colspan="1">2.7 (1.8; 4.0)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Ca &#x0003c;8.4 mg/dl</td><td rowspan="1" colspan="1">1.4 (0.9; 2.0)</td><td rowspan="1" colspan="1">1.8 (1.4; 2.4)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.0002</td></tr><tr><td rowspan="1" colspan="1">PO<sub>4</sub> &#x0003e;5.5 mg/dl</td><td rowspan="1" colspan="1">1.1 (0.9; 1.5)</td><td rowspan="1" colspan="1">1.4 (1.1; 1.7)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.0001</td></tr></tbody></table><table-wrap-foot><fn id="T5TFN1"><p>Effect measures are expressed as a difference in means for quantitative variables and odds ratio for qualitative variables, together with their 95% confidence interval, with respect to the reference subgroup (AV fistula as initial vascular access). For qualitative variables with more than one category, the odds ratio has been calculated with respect to the absence of the displayed category.</p></fn><fn id="T5TFN2"><p><italic>N</italic> = sample size; CKD = chronic kidney disease.</p></fn><fn id="T5TFN3"><p><sup>*</sup>Bonferroni-corrected significance limit: <italic>P</italic> &#x0003c; 0.00022 (0.05/228).</p></fn><fn id="T5TFN4"><p><sup>a</sup>2% patients with PTFE graft not included in the subgroup analysis.</p></fn><fn id="T5TFN5"><p><sup>b</sup>Only analysed in the subgroup of hypertensive patients where the information was available, <italic>N</italic> = 1034.</p></fn></table-wrap-foot></table-wrap></sec><sec id="S3-7"><title>Characteristics of patients with late referral to the nephrologist</title><p>In the subgroup analyses, patients who were referred to the nephrologist &#x0003c;6 months before the start of dialysis had worse functional and nutritional status, a lower degree of dyslipidaemia and hypertension (and more recently diagnosed) and worse residual renal function (higher creatinine and lower 24-h diuresis) than patients who referred &#x0003e;12 months ago (Table <xref ref-type="table" rid="T6">6</xref>). As expected, systemic aetiologies (e.g. myeloma and vasculitis) were also related to the late referral to the nephrologist. Anaemia, hyperferritinaemia and uncontrolled mineral metabolism (hypocalcaemia and hyperphosphataemia) were much more frequently observed in the late referral group. Vascular access was obtained via an AVF in only 25% of patients who were referred late compared with 52&#x02013;64% in the other subgroups.</p><table-wrap id="T6" position="float"><label>Table&#x000a0;6</label><caption><p>Differences in clinical and sociodemographic characteristics of incident haemodialysis patients grouped by duration of predialysis nephrological care (only those variables with significant differences with respect to &#x0003e;12 months patients are displayed)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">&#x02264;6 months (<italic>N</italic> = 610, 27%)</th><th align="left" rowspan="1" colspan="1">7&#x02013;12 months (<italic>N</italic> = 216, 10%)</th><th align="left" rowspan="1" colspan="1">&#x0003e;12 months, reference (<italic>N</italic> = 1386, 63%)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value<sup>*</sup></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Karnofsky scale</td><td rowspan="1" colspan="1">&#x02212;4.1 (&#x02212;5.6; &#x02212;2.3)</td><td rowspan="1" colspan="1">&#x02212;2.5 (&#x02212;4.3; 0.3)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.0001</td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">&#x02212;0.9 (&#x02212;1.4; &#x02212;0.3)</td><td rowspan="1" colspan="1">&#x02212;0.6 (&#x02212;1.4; 0.2)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">CKD aetiology = diabetic &#x02007;nephropathy</td><td rowspan="1" colspan="1">0.8 (0.6; 1.0)</td><td rowspan="1" colspan="1">1.5 (1.1; 2.1)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">CKD aetiology = &#x02007;glomerulonephritis</td><td rowspan="1" colspan="1">0.6 (0.4; 0.9)</td><td rowspan="1" colspan="1">0.5 (0.2; 0.8)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.0002</td></tr><tr><td rowspan="1" colspan="1">CKD aetiology = chronic &#x02007;pyelonephritis</td><td rowspan="1" colspan="1">0.5 (0.3; 0.9)</td><td rowspan="1" colspan="1">0.9 (0.5; 1.7)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.0002</td></tr><tr><td rowspan="1" colspan="1">CKD aetiology = polycystic &#x02007;kidney disease</td><td rowspan="1" colspan="1">0.2 (0.1; 0.4)</td><td rowspan="1" colspan="1">0.2 (0; 0.5)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">CKD aetiology = systemic</td><td rowspan="1" colspan="1">3.2 (2.0; 5.1)</td><td rowspan="1" colspan="1">1.4 (0.6; 3.2)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.0002</td></tr><tr><td rowspan="1" colspan="1">Vascular access = IAVF</td><td rowspan="1" colspan="1">0.1 (0.1; 0.2)</td><td rowspan="1" colspan="1">0.6 (0.4; 0.8)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Diabetes diagnosed &#x0003c;1 year</td><td rowspan="1" colspan="1">15.7 (3.4; 72.4)</td><td rowspan="1" colspan="1">15.9 (3.1; 81.0)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">&#x02007;before<sup>a</sup></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Dyslipaemia</td><td rowspan="1" colspan="1">0.5 (0.4; 0.6)</td><td rowspan="1" colspan="1">0.7 (0.5; 1.0)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Dyslipidaemia diagnosed</td><td rowspan="1" colspan="1">12.3 (7.1; 21.3)</td><td rowspan="1" colspan="1">17.7 (8.7; 35.8)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">&#x02007;&#x0003c;1 year before<sup>b</sup></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Hypertension</td><td rowspan="1" colspan="1">0.3 (0.2; 0.4)</td><td rowspan="1" colspan="1">0.5 (0.3; 0.7)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Hypertension diagnosed</td><td rowspan="1" colspan="1">16.4 (10.3; 26.0)</td><td rowspan="1" colspan="1">12 (6.8; 21.4)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">&#x02007;&#x0003c;1 year before<sup>c</sup></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Malnutrition</td><td rowspan="1" colspan="1">2 (1.5; 2.7)</td><td rowspan="1" colspan="1">1.3 (0.8; 2.1)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Albumin (g/dl)</td><td rowspan="1" colspan="1">&#x02212;0.3 (&#x02212;0.37; &#x02212;0.22)</td><td rowspan="1" colspan="1">&#x02212;0.1 (&#x02212;0.21; 0.01)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Creatinine (mg/dl)</td><td rowspan="1" colspan="1">1.1 (0.8; 1.3)</td><td rowspan="1" colspan="1">&#x02212;0.3 (&#x02212;0.61; 0.01)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">24-h diuresis (ml)</td><td rowspan="1" colspan="1">&#x02212;378 (&#x02212;492; &#x02212;263.9)</td><td rowspan="1" colspan="1">&#x02212;142 (&#x02212;306.3; 22.3)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Haemoglobin &#x0003c;11 g/dl</td><td rowspan="1" colspan="1">3.2 (2.5; 4.0)</td><td rowspan="1" colspan="1">0.9 (0.7; 1.2)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Ferritin &#x02265;500 ng/ml</td><td rowspan="1" colspan="1">2.7 (1.9; 3.8)</td><td rowspan="1" colspan="1">1.2 (0.6; 2.1)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Ca &#x0003c;8.4 mg/dl</td><td rowspan="1" colspan="1">1.9 (1.4; 2.5)</td><td rowspan="1" colspan="1">0.8 (0.5; 1.3)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">PO<sub>4</sub> &#x0003e;5.5 mg/dl</td><td rowspan="1" colspan="1">1.6 (1.3; 1.9)</td><td rowspan="1" colspan="1">0.8 (0.6; 1.1)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr></tbody></table><table-wrap-foot><fn id="T6TFN1"><p>Effect measures are expressed as a difference in means for quantitative variables and odds ratio for qualitative variables, together with their 95% confidence interval, with respect to the reference subgroup (predialysis nephrological care &#x0003e;12 months). For qualitative variables with more than one category, the odds ratio has been calculated with respect to the absence of the displayed category.</p></fn><fn id="T6TFN2"><p><italic>N</italic> = sample size; CKD = chronic kidney disease.</p></fn><fn id="T6TFN3"><p><sup>*</sup>Bonferroni-corrected significance limit: <italic>P</italic> &#x0003c; 0.00022 (0.05/228).</p></fn><fn id="T6TFN4"><p><sup>a</sup>Only analysed in the subgroup of diabetic patients where the information was available, <italic>N</italic> = 460.</p></fn><fn id="T6TFN5"><p><sup>b</sup>Only analysed in the subgroup of dyslipidaemic patients where the information was available, <italic>N</italic> = 512.</p></fn><fn id="T6TFN6"><p><sup>c</sup>Only analysed in the subgroup of hypertensive patients where the information was available, <italic>N</italic> = 1156.</p></fn></table-wrap-foot></table-wrap></sec><sec id="S3-8"><title>Characteristics of patients with previous ischaemic cardiovascular disease</title><p>The presence of previous ischaemic cardiovascular disease in the incident dialysis population was related to all the classic cardiovascular risk factors in the general population (advanced age, male gender, former or current smoker, diabetes mellitus, history of dyslipidaemia or hypertension) except obesity (Table <xref ref-type="table" rid="T7">7</xref>). It is notable that despite a higher percentage of dyslipidaemia and lower HDL-C levels, the mean total cholesterol was lower in the patients with previous cardiovascular disease. This inverse relationship was not due to the greater use of statins in the cardiovascular group (42% versus 58% in the non-cardiovascular groups). Table <xref ref-type="table" rid="T7">7</xref> also shows greater catheter use, worse residual renal function and nutritional status, and a lower degree of hyperphosphataemia in this subgroup of patients.</p><table-wrap id="T7" position="float"><label>Table&#x000a0;7</label><caption><p>Differences in clinical and sociodemographic characteristics of incident haemodialysis patients grouped by the presence of previous ischaemic cardiovascular disease (only those variables with significant differences are displayed)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">With previous ischaemic CVD (<italic>N</italic> = 1640, 70%)</th><th align="left" rowspan="1" colspan="1">Without previous ischaemic CVD, reference (<italic>N</italic> = 701, 30%)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value<sup>*</sup></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">7.3 (5.9; 8)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Karnofsky score</td><td rowspan="1" colspan="1">&#x02212;7.4 (&#x02212;8.4; &#x02212;5.5)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Charlson index</td><td rowspan="1" colspan="1">2.3 (2.1; 2.4)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Male gender</td><td rowspan="1" colspan="1">2 (1.6; 2.5)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">CKD aetiology = diabetic &#x02007;nephropathy</td><td rowspan="1" colspan="1">2.5 (2.0; 3.0)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">CKD aetiology = vascular &#x02007;nephropathy</td><td rowspan="1" colspan="1">2.4 (1.9; 3.0)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Former smoker</td><td rowspan="1" colspan="1">1.8 (1.4; 2.3)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Current smoker</td><td rowspan="1" colspan="1">1.7 (1.2; 2.3)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Employment status = retired</td><td rowspan="1" colspan="1">2.5 (2.0; 3.1)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Vascular access = IAVF</td><td rowspan="1" colspan="1">0.6 (0.5; 0.7)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Diabetes mellitus</td><td rowspan="1" colspan="1">2.7 (2.2; 3.2)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Dyslipidaemia</td><td rowspan="1" colspan="1">2.3 (1.0; 2.7)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Hypertension</td><td rowspan="1" colspan="1">2.7 (1.9; 3.7)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Hypertension diagnosed &#x0003e;5</td><td rowspan="1" colspan="1">2.1 (1.6; 2.8)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">&#x02007;years before<sup>a</sup></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">HbA1c (%)</td><td rowspan="1" colspan="1">0.5 (0.2; 0.7)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.0002</td></tr><tr><td rowspan="1" colspan="1">Albumin (g/dl)</td><td rowspan="1" colspan="1">&#x02212;0.1 (&#x02212;0.16; &#x02212;0.03)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.0002</td></tr><tr><td rowspan="1" colspan="1">Cholesterol (mg/dl)</td><td rowspan="1" colspan="1">&#x02212;8 (&#x02212;12.3; &#x02212;3.6)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">HDL-cholesterol (mg/dl)</td><td rowspan="1" colspan="1">&#x02212;4.5 (&#x02212;7.2; &#x02212;1.7)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Creatinine (mg/dl)</td><td rowspan="1" colspan="1">&#x02212;0.8 (&#x02212;1; &#x02212;0.5)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">24-h diuresis (ml)</td><td rowspan="1" colspan="1">&#x02212;185 (&#x02212;285; &#x02212;84.9)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">PO<sub>4</sub> &#x0003e; 5.5 mg/dl</td><td rowspan="1" colspan="1">0.7 (0.6; 0.8)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.0002</td></tr></tbody></table><table-wrap-foot><fn id="T7TFN1"><p>Effect measures are expressed as a difference in means for quantitative variables and odds ratio for qualitative variables, together with their 95% confidence interval, with respect to the reference subgroup (non-previous ischaemic cardiovascular disease). For qualitative variables with more than one category, the odds ratio has been calculated with respect to the absence of the displayed category.</p></fn><fn id="T7TFN2"><p><italic>N</italic> = sample size; CKD = chronic kidney disease; CVD = cardiovascular disease.</p></fn><fn id="T7TFN3"><p><sup>*</sup>Bonferroni-corrected significance limit: <italic>P</italic> &#x0003c; 0.00022 (0.05/228).</p></fn><fn id="T7TFN4"><p><sup>a</sup>Only analysed in the subgroup of hypertensive patients where the information was available, <italic>N</italic> = 1174.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="S4"><title>Discussion</title><p>ANSWER is the first large, prospective, observational study of incident haemodialysis patients in Spain, which will help to clarify, together with other recent ongoing studies in Europe (the Netherlands [<xref ref-type="bibr" rid="R7 R8">7,8</xref>], France [<xref ref-type="bibr" rid="R10 R11 R12">10&#x02013;12</xref>], Italy [<xref ref-type="bibr" rid="R13 R14">13,14</xref>] and Sweden [<xref ref-type="bibr" rid="R15">15</xref>]) and North America (CHOICE [<xref ref-type="bibr" rid="R29">29</xref>], Wave-2 USRDS [<xref ref-type="bibr" rid="R30 R31 R32">30&#x02013;32</xref>]), the risk factors associated with cardiovascular morbidity and mortality in these patients. The ANSWER study enrolled all consecutive incident haemodialysis patients, whereas most other haemodialysis studies have excluded patients who did not survive the first 3 months [<xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R29">29</xref>,<xref ref-type="bibr" rid="R31">31</xref>] or have included &#x02018;prevalent&#x02019; patients (DOPPS [<xref ref-type="bibr" rid="R33">33</xref>], MAR [<xref ref-type="bibr" rid="R34">34</xref>]). Studies of &#x02018;incident&#x02019; populations are needed to verify the previously described associations for &#x02018;prevalent&#x02019; populations, because those studies suffered from the bias of not enrolling patients with higher cardiovascular risk, that is, those who die in the first months after dialysis onset.</p><p>The sociodemographic characteristics of our cohort are similar to those reported for other European incident populations. The mean age and percentage of patients older than 65 or 75 years in our sample are similar to those reported in other European countries [<xref ref-type="bibr" rid="R8 R9 R10">8&#x02013;10</xref>,<xref ref-type="bibr" rid="R14">14</xref>]) and the USA [<xref ref-type="bibr" rid="R35">35</xref>].</p><p>About a quarter of the patients developed renal failure due to diabetic nephropathy. This figure is similar to that reported in other European studies [<xref ref-type="bibr" rid="R12 R13">12,13</xref>,<xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R36">36</xref>&#x02013;<xref ref-type="bibr" rid="R38">38</xref>]. The prevalence of vascular nephropathy in the present study is also similar to that reported in other Spanish and Italian studies [<xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R16">16</xref>], but it seems slightly lower than the prevalence reported from the Netherlands [<xref ref-type="bibr" rid="R8">8</xref>] or France [<xref ref-type="bibr" rid="R9 R10">9,10</xref>,<xref ref-type="bibr" rid="R12">12</xref>]. Our results support the findings of L&#x000f3;pez Revuelta and colleagues [<xref ref-type="bibr" rid="R16">16</xref>] that the aetiology of chronic kidney disease in European incident haemodialysis populations is different from the aetiology among the incident population in the USA, where diabetes and hypertension account for &#x0003e;70% of cases, compared with &#x0003c;50% in Europe.</p><p>Due to the high mean age of the study population and significant prevalence of comorbidities, the functional status was moderately affected, consistent with findings of previous Spanish studies in the incident haemodialysis population [<xref ref-type="bibr" rid="R38">38</xref>]. Interestingly, the functional status in our patients is better than that of incident patients in the UK of similar mean age [<xref ref-type="bibr" rid="R39 R40">39,40</xref>], but is similar to that of American patients, who were an average of 10 years younger [<xref ref-type="bibr" rid="R41">41</xref>]. The gender distribution in both the UK and US samples was different from ours (more males in the UK and US samples), but the worse functional status of the UK sample may be related to the higher proportion of unplanned initiation of haemodialysis in that population (44&#x02013;47%) [<xref ref-type="bibr" rid="R39 R40">39,40</xref>]. The QoL results revealed severely affected physical and mental health, similar to previous reports of Spanish incident haemodialysis patients [<xref ref-type="bibr" rid="R42 R43">42,43</xref>].</p><p>Regarding the use of catheter as first vascular access, we found fewer shunts than reported in the DOPPS study for Spain. This may be attributed to the differences among recruiting facilities [<xref ref-type="bibr" rid="R44 R45">44,45</xref>]. The fact that there are many more facilities participating in the ANSWER study (147 compared with 20 in the DOPPS) probably provides a more confident estimate of the real situation of vascular access in Spain. Furthermore, our results are in agreement with previous studies in Spain, in which between 46% and 51% of incident patients were found not to have permanent AVF access [<xref ref-type="bibr" rid="R49">46</xref>,<xref ref-type="bibr" rid="R47">47</xref>], and this proportion has remained stable during the past few years [<xref ref-type="bibr" rid="R48">48</xref>].</p><p>Although a minimum nephrological follow-up of 6 months prior to haemodialysis onset is recommended, late referral has been reported for about a quarter of Spanish incident patients, similar to previous findings from other European countries [<xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R49">49</xref>,<xref ref-type="bibr" rid="R50">50</xref>]. The high proportion of catheter use in the late referral group, also described in DOPPS [<xref ref-type="bibr" rid="R51">51</xref>], highlights the need for early referral as far as possible. A shorter time of nephrologist follow-up has been associated with higher mortality in haemodialysis patients independent of catheter vascular access [<xref ref-type="bibr" rid="R52">52</xref>], indicating the presence of other negative factors in these patients. The worse clinical status at the onset of haemodialysis in the late referral subgroup may contribute to this phenomenon [<xref ref-type="bibr" rid="R53 R54">53,54</xref>].</p><p>With respect to kidney function at haemodialysis onset in our patients, the GFR was lower in our patients compared with reports from previous studies in Spain and other European countries [<xref ref-type="bibr" rid="R49 R50">49,50</xref>,<xref ref-type="bibr" rid="R55">55</xref>], and 8 in 10 patients were below the limit of 10 ml/min recommended by the K/DOQI guidelines [<xref ref-type="bibr" rid="R56">56</xref>]. These data suggest a delayed onset of haemodialysis in our settings. Initiation of haemodialysis above this limit may prolong survival according to the NECOSAD study [<xref ref-type="bibr" rid="R57">57</xref>]. Other haemodialysis quality indicators, such as the low initial eKt/V, also suggest inadequate haemodialysis onset although almost half the patients are using high-flux membranes.</p><p>About 10% of the population had history of neoplasia. This figure is a bit higher than that reported for the Spanish DOPPS cohort (6%), but agrees with the 9% of the EURO-DOPPS [<xref ref-type="bibr" rid="R36">36</xref>] prevalent patients and also with the 11% reported for the incident French population [<xref ref-type="bibr" rid="R10">10</xref>] (although that study considered only active neoplasia).</p><p>The antecedents of cardiovascular disease in our sample were, as expected, very common. The prevalence of ischaemic heart disease was similar to that in Italy, France and Sweden [<xref ref-type="bibr" rid="R11">11</xref>,<xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R15">15</xref>,<xref ref-type="bibr" rid="R58">58</xref>], but lower than that in the UK, Germany and the USA [<xref ref-type="bibr" rid="R58">58</xref>,<xref ref-type="bibr" rid="R35">35</xref>]. The prevalence of peripheral vascular disease was similar to that in Sweden and the USA [<xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R35">35</xref>], but lower than the prevalence in France, Germany, Italy and the UK [<xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R11">11</xref>,<xref ref-type="bibr" rid="R58">58</xref>]. The prevalence of heart failure was similar to that in France, Germany and Italy [<xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R58">58</xref>], but lower than the prevalence in the UK and the USA [<xref ref-type="bibr" rid="R58">58</xref>,<xref ref-type="bibr" rid="R35">35</xref>]. Finally, the prevalence of cerebrovascular disease was a little higher than or similar to that in Italy, France, Sweden and the USA [<xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R11">11</xref>,<xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R15">15</xref>,<xref ref-type="bibr" rid="R35">35</xref>]. The differences in these prevalences must be viewed with caution, as they may be related to different disease definitions or methods of collection.</p><p>With regard to the prevalence of classic cardiovascular risk factors, the majority of patients had uncontrolled hypertension, despite almost all patients receiving antihypertensive treatment. Diabetes affected one-third of our patients, similar to other European studies [<xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R15">15</xref>], and far from one-half in the USA [<xref ref-type="bibr" rid="R59">59</xref>,<xref ref-type="bibr" rid="R35">35</xref>]. Glycaemic control was poor, and 1 in 5 patients were obese. Both the proportion of obese patients and the mean BMI were highly consistent with the findings from almost all previously described incident European and North American populations [<xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R15">15</xref>,<xref ref-type="bibr" rid="R32">32</xref>,<xref ref-type="bibr" rid="R35">35</xref>,<xref ref-type="bibr" rid="R50">50</xref>,<xref ref-type="bibr" rid="R59">59</xref>]. However, malnutrition was less prevalent in our sample than in the Netherlands or Sweden [<xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R15">15</xref>]. This discordance is probably due to an underestimation of malnutrition by Spanish physicians, as one-third of our patients had low albumin levels. The high prevalence of other emergent cardiovascular risk factors (hyperhomocysteinaemia, hyperfibrinogenaemia and elevated lipoprotein (a)) in our sample with respect to the general Spanish population [<xref ref-type="bibr" rid="R60">60</xref>] agrees with previous results in maintenance [<xref ref-type="bibr" rid="R61">61</xref>] and incident [<xref ref-type="bibr" rid="R10">10</xref>] haemodialysis patients. Since this is a cross-sectional analysis, the causal relationship between all these findings and cardiovascular status cannot be verified. Future data will produce more reliable results regarding the predictive value of the collected variables.</p><p>Anaemia-related target ranges, which are strongly predictive of reduced mortality in chronic kidney disease [<xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R6">6</xref>], were achieved by a relatively low percentage of patients. Despite almost 1 in 2 patients receiving ESAs prior to haemodialysis onset, &#x0003e;50% were anaemic, and more than one-third had iron deficiency, which suggests incorrect ESA administration and insufficient correction of iron stores. Less than 1 in 10 patients were within the K/DOQI targets for all four bone and mineral metabolism parameters, iPTH being the most uncontrolled. These findings correlate with those from the NECOSAD study [<xref ref-type="bibr" rid="R7">7</xref>]. Data from prevalent populations indicate that the degree of control of bone mineral disease is not better after the onset of haemodialysis [<xref ref-type="bibr" rid="R62">62</xref>]. Studies of the recently available therapies (calcimimetics, calcium-free P-chelating agents or new vitamin D analogues) may help to resolve this issue in the near future.</p><p>With regard to the classic cardiovascular risk factors, the expected associations with previous smoking, dyslipidaemia, hypertension and diabetes were observed in patients with a history of cardiovascular disease. However, the cholesterol levels were lower in the group with cardiovascular disease, which could be related to the worse nutritional status in those patients.</p><p>This cohort study has some limitations. The non-random (but consecutive) patient selection may have resulted in some selection bias. However, the extended inclusion period and the fact that the final sample represents more than half of all incident Spanish patients during this period [<xref ref-type="bibr" rid="R27 R28">27,28</xref>] support the validity of the recruited cohort. In addition, as enrolment at each site was stratified according to the incidence of haemodialysis in a reference population, the 2341 patients in the study were considered to be representative of the target population in Spain.</p><p>For the purposes of international comparisons, our study confirms that there are important differences in the prevalence of cardiovascular and mortality risk factors, especially with respect to North American populations. Spain has an extremely high rate of renal transplantation (47% of patients on renal replacement therapy in 2004 [<xref ref-type="bibr" rid="R28">28</xref>] versus 29% in the USA [<xref ref-type="bibr" rid="R63">63</xref>]). This should be taken into account when comparing the prospective cardiovascular morbidity and mortality results in the future.</p><p>In summary, the ANSWER study provides valuable new data, thus adding to our knowledge of the characteristics of incident haemodialysis patients in Spain and Europe. Most patients present at an advanced age and have hypertension, diabetes and previous cardiovascular disease. Their functional status is moderately affected, considering the high mean age. Our results also show that in the Spanish setting, haemodialysis is started too late and that patients are also referred too late to the nephrologist (late referral for 1 in 4 patients with diabetic and vascular nephropathy). Also, not enough effort was made to place a permanent AVF before haemodialysis onset in patients referred &#x0003e;6 months ago, and such efforts must be specially made in older and diabetic patients.</p><p>This study has also revealed an extremely high prevalence of emergent and uraemia-related cardiovascular risk factors and poor glycaemic control, low HDL-C, hypertension, anaemia, malnutrition, hypo- and hyperparathyroidism, hyperphosphataemia and hypo- and hypercalcaemia. These results reflect the need for improving the therapeutic management of incident dialysis patients before the onset of haemodialysis.</p></sec></body><back><ack><p>This study was supported in part by a grant from Amgen, S.A., Spain. Writing assistance was supported by Amgen. The authors wish to thank all participating investigators of the ANSWER study: P. Abrigar; J. Aguilera; M.J. Aladr&#x000e9;n; M. Alcal&#x000e1;; R. Alegre; M.A. Aliaga; J. Almirall; R. Alonso; R. Alvarez; R. Amador; M.L. Amoedo; B. Andr&#x000e9;s; P. Angelet; A. Antol&#x000ed;n; M. Arambarri; M.D. Arenas; A. Argoitia; M. Arranz; A. Arraque; G. Arribas; J. Arrieta; M.J. Arroyo; J. Arteaga; B. Aurrekoetxea; B. Avil&#x000e9;s; Y. Aznar; F. Barbosa; G. Barril; M.A. Basterrechea; M. Belart; S. Beltran; G. Bernal; A. Bernat; M.E. Besada; A. Betriu; M.M. Biechy; A. Blanco; A. Blasco; L. Bola&#x000f1;os; B. Bonilla; A. Bordils; A. Botella; J.J. Bravo; M.T. Calder&#x000f3;n; J. Calls; J. Calpe; C. Calvar; J.A. Calvi&#x000f1;o; E. Calvo; G. Camacho; A. Cardoso; P. Caro; M.A. Carret&#x000f3;n; A. Cases; I. Castellano; E. Castellote; R. Causadias; M. Ceballos; J. Cebollada; S. Cerezo; M.C. Cid; M.T. Compte; J. Contreras; A. Covarsi; L. Craver; A. Crespo; J.M. Cruzado; A. Cubas; X. Cuevas; M. Cuxart; A.I. D&#x000ed;az; C. D&#x000ed;az; H. D&#x000ed;az; J. Diego; M.L. Dom&#x000ed;nguez; C.A. Donapetry; V. Dur&#x000e1;n; S. Fabado; M.A. Fenollosa; E. Fern&#x000e1;ndez; E.J. Fern&#x000e1;ndez; J. Fern&#x000e1;ndez; J.E. Fern&#x000e1;ndez; M.A. Fern&#x000e1;ndez; M.D. Fern&#x000e1;ndez; N. Fontser&#x000e9;; J. Fort; A. Fraile; P. Fraile; R. Franquelo; E. Gago; M.J. Gal&#x000e1;n; A. Gallego; A. G&#x000e1;mez; C. G&#x000e1;mez; A. Garc&#x000ed;a; C. Garc&#x000ed;a; C.M. Garc&#x000ed;a; F. Garc&#x000ed;a; I. Garc&#x000ed;a; J. Garc&#x000ed;a; J.A. Garc&#x000ed;a; J.B. Garc&#x000ed;a; M. Garc&#x000ed;a; M.J. Garc&#x000ed;a; M.M. Garc&#x000ed;a; M.T. Garc&#x000ed;a; O. Garc&#x000ed;a; R. Garc&#x000ed;a; S.A. Garc&#x000ed;a; Z. Garc&#x000ed;a; E. Garrig&#x000f3;s; R. Gauna; J.M. Gil; M.T. Gil; I. Gimeno; J.D. Gir&#x000e1;ldez; J.R. G&#x000f3;mez; M.A. Gonzalez; A. Gonz&#x000e1;lez; B. Gonz&#x000e1;lez; F.J. Gonz&#x000e1;lez; F.M. Gonz&#x000e1;lez; J. Gonz&#x000e1;lez; M. Go&#x000f1;i; R. Gota; M.C. Gracia; I. Granado; M. Granda; J. Grande; J.M. Gra&#x000f1;a; E. Gruss; I. Guerrero; C.S. Guerv&#x000f3;s; M.D. G&#x000fc;imil; A. Guzm&#x000e1;n; M. Heral; M. Heras; J. Hern&#x000e1;ndez; M.T. Hern&#x000e1;ndez; J.A. Herrero; J.C. Herrero; C.J. Hornos; I. Iribar; J.M. Irrizu; M. Jim&#x000e9;nez; P.J. Labrador; M. Lago; I. Lampreabe; B. Le&#x000f3;n; R. Ll&#x000f3;pez; A. Llopis; J.M. Logro&#x000f1;o; D. L&#x000f3;pez; E. L&#x000f3;pez; F. L&#x000f3;pez; J. L&#x000f3;pez; J.L. L&#x000f3;pez; M. L&#x000f3;pez; M.O. L&#x000f3;pez; T. L&#x000f3;pez; I. Lorenzo; J. Lorenzo; V. Lorenzo; M.A. Macia; L. Marcas; J. Marco; N. Marigliano; A. Mar&#x000ed;n; B. Mart&#x000ed;n; F. Mart&#x000ed;n; G. Mart&#x000ed;n; J. Mart&#x000ed;n; P. Mart&#x000ed;n; A. Martinez; P. Mart&#x000ed;nez; C. Massanet; M. Matas; P. Mateos; P. Mateos; J.M. Mauri; M.L. Medina; J.L. Miguel; I. Mill&#x000e1;n; E. Miranda; J. M&#x000f2;dol; I. Moina; P. Molina; J. Montenegro; C. Montoyo; B. Moragrega; M.V. Moreno; R. Moreno; R. Mouzo; M.L. Mu&#x000f1;iz; A.B. Mu&#x000f1;oz; C. Mu&#x000f1;oz; J.M. Mu&#x000f1;oz; S. Muray; J. Naranjo; M. Naranjo; M. Navarro; M.J. Navarro; R. Novillos; J. N&#x000fa;&#x000f1;ez; P. Oleo; J. Olivares; J.&#x000c1;. Oliver; R. Ordo&#x000f1;ez; M. Ortega; M.D. Ort&#x000ed;; J.M. Osorio; A. Otero; A. Palma; J.M. Pastor; J. Pay&#x000e1;n; B. Pazos; A. P&#x000e9;rez; C. P&#x000e9;rez; M.A. P&#x000e9;rez; R. P&#x000e9;rez; A. Peris; M. Picazo; M. Pifarr&#x000e9;; M.D. Pino; V.C. Pi&#x000f1;era; J.L. Pizarro; M. Pons; J.M. Portoles; M.M. Pousa; C. Pozo; M.C. Prados; M.D. Prados; M. Prieto; J. Prim; B. Ramos; C. Ramos; I. Ramos; N. Ramos; A. Rif&#x000e0;; B. Rinc&#x000f3;n; E.A. Rivas; R. Roca; A. Rodr&#x000ed;guez; J.R. Rodr&#x000ed;guez; M.I. Rodr&#x000ed;guez; M.L. Rodr&#x000ed;guez; P. Rodr&#x000ed;guez; J. Romero; E. Rubio; A. Ruiz; A.M. Ruiz; J. Ruiz; J.E. Ruiz; P. Ruiz; R. Ruiz; C. S&#x000e1;nchez; E. S&#x000e1;nchez; F. S&#x000e1;nchez; I. S&#x000e1;nchez; M. S&#x000e1;nchez; M.C. S&#x000e1;nchez; M.D. S&#x000e1;nchez; O. S&#x000e1;nchez; P. S&#x000e1;nchez; D. S&#x000e1;nchez-Guisande; J. Sancho; R. Sans; C. Santamar&#x000ed;a; F. Sastre; M. Serra; M. Serra; A. Serrano; M. Sevilla; T. Sierra; G. Silgado; J. Sobrado; A. Soldevila; J.M. Soler; S. Tall&#x000f3;n; A. Tato; A. Toledo; F. Tornero; I. Torregrosa; G. Torres; J. Us&#x000f3;n; J. Vald&#x000e9;s; A. Valera; V. Valverde; M. Vera; F. Vidaur; J. Viladoms and M.T. Villaverde.</p><p><italic>Conflict of interest statement.</italic> Fina Llad&#x000f3;s and Javier Lozano are employees of AMGEN Inc. There is no other conflict of interest.</p></ack><ref-list><title>References</title><ref id="R1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pozzoni</surname><given-names>P</given-names></name><name><surname>Del Vecchio</surname><given-names>L</given-names></name><name><surname>Pontoriero</surname><given-names>G</given-names></name><etal/></person-group><article-title>Long-term outcome in hemodialysis: morbidity and mortality</article-title><source>J Nephrol</source><year>2004</year><volume>17</volume><fpage>S87</fpage><lpage>S95</lpage><pub-id pub-id-type="pmid">15599892</pub-id></citation></ref><ref id="R2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Foley</surname><given-names>RN</given-names></name><name><surname>Parfrey</surname><given-names>PS</given-names></name><name><surname>Sarnak</surname><given-names>MJ</given-names></name></person-group><article-title>Epidemiology of cardiovascular disease in chronic renal disease</article-title><source>J Am Soc Nephrol</source><year>1998</year><volume>9</volume><issue>Suppl 12</issue><fpage>16</fpage><lpage>23</lpage></citation></ref><ref id="R3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hegarty</surname><given-names>J</given-names></name><name><surname>Foley</surname><given-names>RN</given-names></name></person-group><article-title>Anaemia, renal insufficiency and cardiovascular outcome</article-title><source>Nephrol Dial Transplant</source><year>2001</year><volume>16</volume><issue>Suppl 1</issue><fpage>102</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">11369834</pub-id></citation></ref><ref id="R4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goodkin</surname><given-names>DA</given-names></name><name><surname>Mapes</surname><given-names>DL</given-names></name><name><surname>Held</surname><given-names>PJ</given-names></name></person-group><article-title>The dialysis outcomes and practice patterns study (DOPPS): how can we improve the care of hemodialysis patients?</article-title><source>Semin Dial</source><year>2001</year><volume>14</volume><fpage>157</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">11422917</pub-id></citation></ref><ref id="R5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trespalacios</surname><given-names>FC</given-names></name><name><surname>Taylor</surname><given-names>AJ</given-names></name><name><surname>Agodoa</surname><given-names>LY</given-names></name><etal/></person-group><article-title>Incident acute coronary syndromes in chronic dialysis patients in the United States</article-title><source>Kidney Int</source><year>2002</year><volume>62</volume><fpage>1799</fpage><lpage>1805</lpage><pub-id pub-id-type="pmid">12371982</pub-id></citation></ref><ref id="R6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stack</surname><given-names>AG</given-names></name><name><surname>Bloembergen</surname><given-names>WE</given-names></name></person-group><article-title>Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study</article-title><source>J Am Soc Nephrol</source><year>2001</year><volume>12</volume><fpage>1516</fpage><lpage>1523</lpage><pub-id pub-id-type="pmid">11423581</pub-id></citation></ref><ref id="R7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Merkus</surname><given-names>MP</given-names></name><name><surname>Jager</surname><given-names>KJ</given-names></name><name><surname>Dekker</surname><given-names>FW</given-names></name><etal/><collab>The NECOSAD Study Group</collab></person-group><article-title>Predictors of poor outcome in chronic dialysis patients: the Netherlands Cooperative Study on the Adequacy of Dialysis</article-title><source>Am J Kidney Dis</source><year>2000</year><volume>35</volume><fpage>69</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">10620547</pub-id></citation></ref><ref id="R8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noordzij</surname><given-names>M</given-names></name><name><surname>Korevaar</surname><given-names>JC</given-names></name><name><surname>Bos</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients</article-title><source>Nephrol Dial Transplant</source><year>2006</year><volume>21</volume><fpage>2513</fpage><lpage>2520</lpage><pub-id pub-id-type="pmid">16799173</pub-id></citation></ref><ref id="R9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jungers</surname><given-names>P</given-names></name><name><surname>Choukroun</surname><given-names>G</given-names></name><name><surname>Robino</surname><given-names>C</given-names></name><etal/></person-group><article-title>Epidemiology of end-stage renal disease in the Ile-de-France area: a prospective study in 1998</article-title><source>Nephrol Dial Transplant</source><year>2000</year><volume>15</volume><fpage>2000</fpage><lpage>2006</lpage><pub-id pub-id-type="pmid">11096146</pub-id></citation></ref><ref id="R10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pernod</surname><given-names>G</given-names></name><name><surname>Bosson</surname><given-names>JL</given-names></name><name><surname>Golshayan</surname><given-names>D</given-names></name><etal/></person-group><article-title>The Diamant Alpin Dialysis Cohort Study: clinico-biological characteristics and cardiovascular genetic risk profile of incident patients</article-title><source>J Nephrol</source><year>2004</year><volume>17</volume><fpage>66</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">15151261</pub-id></citation></ref><ref id="R11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pernod</surname><given-names>G</given-names></name><name><surname>Bosson</surname><given-names>JL</given-names></name><name><surname>Golshayan</surname><given-names>D</given-names></name><etal/></person-group><article-title>Phenotypic and genotypic risk factors for cardiovascular events in an incident dialysis cohort</article-title><source>Kidney Int</source><year>2006</year><volume>69</volume><fpage>1424</fpage><lpage>1430</lpage><pub-id pub-id-type="pmid">16557227</pub-id></citation></ref><ref id="R12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Villar</surname><given-names>E</given-names></name><name><surname>Remontet</surname><given-names>L</given-names></name><name><surname>Labeeuw</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effect of age, gender, and diabetes on excess death in end-stage renal failure</article-title><source>J Am Soc Nephrol</source><year>2007</year><volume>18</volume><fpage>2125</fpage><lpage>2134</lpage><pub-id pub-id-type="pmid">17582163</pub-id></citation></ref><ref id="R13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Benedetto</surname><given-names>A</given-names></name><name><surname>Marcelli</surname><given-names>D</given-names></name><name><surname>D&#x02019;Andrea</surname><given-names>A</given-names></name><etal/></person-group><article-title>Risk factors and underlying cardiovascular diseases in incident ESRD patients</article-title><source>J Nephrol</source><year>2005</year><volume>18</volume><fpage>592</fpage><lpage>598</lpage><pub-id pub-id-type="pmid">16299687</pub-id></citation></ref><ref id="R14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Locatelli</surname><given-names>F</given-names></name><name><surname>Marcelli</surname><given-names>D</given-names></name><name><surname>Conte</surname><given-names>F</given-names></name><etal/></person-group><article-title>Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease</article-title><source>J Am Soc Nephrol</source><year>2001</year><volume>12</volume><fpage>2411</fpage><lpage>2417</lpage><pub-id pub-id-type="pmid">11675417</pub-id></citation></ref><ref id="R15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>H</given-names></name><name><surname>Qureshi</surname><given-names>AR</given-names></name><name><surname>Heimb&#x000fc;rger</surname><given-names>O</given-names></name><etal/></person-group><article-title>Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD</article-title><source>Am J Kidney Dis</source><year>2006</year><volume>47</volume><fpage>139</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">16377395</pub-id></citation></ref><ref id="R16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez Revuelta</surname><given-names>K</given-names></name><name><surname>Saracho</surname><given-names>R</given-names></name><name><surname>Garc&#x000ed;a L&#x000f3;pez</surname><given-names>F</given-names></name><etal/></person-group><article-title>Informe de di&#x000e1;lisis y trasplante a&#x000f1;o 2001 de la Sociedad Espa&#x000f1;ola de Nefrolog&#x000ed;a y Registros Auton&#x000f3;micos</article-title><source>Nefrolog&#x000ed;a</source><year>2004</year><volume>24</volume><fpage>21</fpage><lpage>33</lpage></citation></ref><ref id="R17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Altisent</surname><given-names>R</given-names></name><name><surname>C&#x000f3;rdoba</surname><given-names>R</given-names></name><name><surname>Martin</surname><given-names>JM</given-names></name></person-group><article-title>Criterios operativos para le prevenci&#x000f3;n del alcoholismo</article-title><source>Med Clin (Barc)</source><year>1992</year><volume>99</volume><fpage>584</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">1460915</pub-id></citation></ref><ref id="R18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Charlson</surname><given-names>ME</given-names></name><name><surname>Pompei</surname><given-names>P</given-names></name><name><surname>Ales</surname><given-names>KL</given-names></name><etal/></person-group><article-title>A new method of classifying prognostic comorbidity in longitudinal studies: development and validation</article-title><source>J Chron Dis</source><year>1987</year><volume>40</volume><fpage>373</fpage><lpage>383</lpage><pub-id pub-id-type="pmid">3558716</pub-id></citation></ref><ref id="R19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Charlson</surname><given-names>M</given-names></name><name><surname>Szatrowski</surname><given-names>TP</given-names></name><name><surname>Peterson</surname><given-names>J</given-names></name><etal/></person-group><article-title>Validation of a combined comorbidity index</article-title><source>J Clin Epidemiol</source><year>1994</year><volume>47</volume><fpage>1245</fpage><lpage>1251</lpage><pub-id pub-id-type="pmid">7722560</pub-id></citation></ref><ref id="R20"><label>20</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>J</given-names></name><name><surname>Snow</surname><given-names>KK</given-names></name><name><surname>Kosinski</surname><given-names>M</given-names></name><etal/></person-group><source>SF-36 Health Survey: Manual and Interpretation Guide</source><year>1993</year><publisher-loc>Boston, MA</publisher-loc><publisher-name>The Health Institute, New England Medical Center</publisher-name></citation></ref><ref id="R21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alonso</surname><given-names>J</given-names></name><name><surname>Prieto</surname><given-names>L</given-names></name><name><surname>Ant&#x000f3;</surname><given-names>JM</given-names></name></person-group><article-title>La versi&#x000f3;n espa&#x000f1;ola del SF-36 Health Survey (Cuestionario de Salud SF-36): un instrumento para la medida de los resultados cl&#x000ed;nicos</article-title><source>Med Clin (Barc)</source><year>1995</year><volume>104</volume><fpage>771</fpage><lpage>776</lpage><pub-id pub-id-type="pmid">7783470</pub-id></citation></ref><ref id="R22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Daugirdas</surname><given-names>JT</given-names></name></person-group><article-title>Simplified equations for monitoring Kt/V, PCRn, eKt/V, and ePCRn</article-title><source>Adv Ren Replace Ther</source><year>1995</year><volume>2</volume><fpage>295</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">8591121</pub-id></citation></ref><ref id="R23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levey</surname><given-names>AS</given-names></name><name><surname>Bosch</surname><given-names>JP</given-names></name><name><surname>Lewis</surname><given-names>JB</given-names></name><etal/></person-group><article-title>A more accurate method to estimate glomerular filtration equation from serum creatinine: a new prediction equation</article-title><source>Ann Intern Med</source><year>1999</year><volume>130</volume><fpage>461</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">10075613</pub-id></citation></ref><ref id="R24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><collab>National Kidney Foundation (NKF) K/DOQI Guidelines</collab></person-group><article-title>K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease</article-title><source>Am J Kidney Dis</source><year>2003</year><volume>42</volume><fpage>S7</fpage><lpage>S201</lpage></citation></ref><ref id="R25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Locatelli</surname><given-names>F</given-names></name><name><surname>Aljama</surname><given-names>P</given-names></name><name><surname>B&#x000e1;r&#x000e1;ny</surname><given-names>P</given-names></name><etal/></person-group><article-title>Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure</article-title><source>Nephrol Dial Transplant</source><year>2004</year><volume>19</volume><issue>Suppl 2</issue><fpage>ii1</fpage><lpage>ii47</lpage><pub-id pub-id-type="pmid">15206425</pub-id></citation></ref><ref id="R26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bland</surname><given-names>JM</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Multiple significance tests: the Bonferroni method</article-title><source>BMJ</source><year>1995</year><volume>310</volume><fpage>170</fpage><pub-id pub-id-type="pmid">7833759</pub-id></citation></ref><ref id="R27"><label>27</label><citation citation-type="other"><article-title>Sociedad Espa&#x000f1;ola deNefrolog&#x000ed;a-Grupo deRegistros deEnfermos Renales</article-title><comment><italic>Informe de Di&#x000e1;lisis y Trasplante</italic>, 2003; SEN 2004</comment></citation></ref><ref id="R28"><label>28</label><citation citation-type="journal"><article-title>Sociedad Espa&#x000f1;ola deNefrolog&#x000ed;a-Grupo deRegistros deEnfermos Renales</article-title><comment><italic>Informe de Di&#x000e1;lisis y Trasplante</italic>, 2004; SEN 2005</comment></citation></ref><ref id="R29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miskulin</surname><given-names>DC</given-names></name><name><surname>Meyer</surname><given-names>KB</given-names></name><name><surname>Athienites</surname><given-names>NV</given-names></name><etal/></person-group><article-title>Comorbidity and other factors associated with modality selection in incident dialysis patients: the CHOICE Study. Choices for Healthy Outcomes in Caring for End-Stage Renal Disease</article-title><source>Am J Kidney Dis</source><year>2002</year><volume>39</volume><fpage>324</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">11840373</pub-id></citation></ref><ref id="R30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishani</surname><given-names>A</given-names></name><name><surname>Collins</surname><given-names>AJ</given-names></name><name><surname>Herzog</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Septicemia, access and cardiovascular disease in dialysis patients: the USRDS Wave 2 study</article-title><source>Kidney Int</source><year>2005</year><volume>68</volume><fpage>311</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">15954922</pub-id></citation></ref><ref id="R31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Lacson</surname><given-names>E</given-names><suffix>Jr</suffix></name><name><surname>Lowrie</surname><given-names>EG</given-names></name><etal/></person-group><article-title>The epidemiology of systolic blood pressure and death risk in hemodialysis patients</article-title><source>Am J Kidney Dis</source><year>2006</year><volume>48</volume><fpage>606</fpage><lpage>615</lpage><pub-id pub-id-type="pmid">16997057</pub-id></citation></ref><ref id="R32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>M</given-names></name><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Gutierrez</surname><given-names>O</given-names></name><etal/></person-group><article-title>Vitamin D levels and early mortality among incident hemodialysis patients</article-title><source>Kidney Int</source><year>2007</year><volume>72</volume><fpage>1004</fpage><lpage>1013</lpage><pub-id pub-id-type="pmid">17687259</pub-id></citation></ref><ref id="R33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rayner</surname><given-names>HC</given-names></name><name><surname>Pisoni</surname><given-names>RL</given-names></name><name><surname>Bommer</surname><given-names>J</given-names></name><etal/></person-group><article-title>Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)</article-title><source>Nephrol Dial Transplant</source><year>2004</year><volume>19</volume><fpage>108</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">14671046</pub-id></citation></ref><ref id="R34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Portol&#x000e9;s</surname><given-names>J</given-names></name><name><surname>L&#x000f3;pez-G&#x000f3;mez</surname><given-names>JM</given-names></name><name><surname>Aljama</surname><given-names>P</given-names></name></person-group><article-title>Riesgo cardiovascular en hemodi&#x000e1;lisis en Espa&#x000f1;a: prevalencia, pautas de actuaci&#x000f3;n y objetivos (estudio MAR)</article-title><source>Nefrologia</source><year>2005</year><volume>25</volume><fpage>297</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">16053011</pub-id></citation></ref><ref id="R35"><label>35</label><citation citation-type="other"><person-group person-group-type="author"><collab>United States Renal Data System</collab></person-group><year>2006</year><comment><italic>2006 Annual Data Report</italic>. National Institutes of Health, National Institute of Diabetes &#x00026; Digestive &#x00026; Kidney Diseases, Division of Kidney, Urologic, &#x00026; Hematologic Diseases</comment></citation></ref><ref id="R36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cruz</surname><given-names>PM</given-names></name><name><surname>Piera</surname><given-names>L</given-names></name><name><surname>Bragg-Gresham</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Results of the international hemodialysis study DOPPS in Spain and Europe</article-title><source>Nefrologia</source><year>2003</year><volume>23</volume><fpage>437</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">14658170</pub-id></citation></ref><ref id="R37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hecking</surname><given-names>E</given-names></name><name><surname>Bragg-Gresham</surname><given-names>JL</given-names></name><name><surname>Rayner</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Haemodialysis prescription, adherence and nutritional indicators in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)</article-title><source>Nephrol Dial Transplant</source><year>2004</year><volume>19</volume><fpage>100</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">14671045</pub-id></citation></ref><ref id="R38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vald&#x000e9;s</surname><given-names>C</given-names></name><name><surname>Garc&#x000ed;a-Mendoza</surname><given-names>M</given-names></name><name><surname>Rebollo</surname><given-names>P</given-names></name><etal/></person-group><article-title>Mental health at the third month of haemodialysis as a predictor of short-term survival</article-title><source>Nephrol Dial Transplant</source><year>2006</year><volume>21</volume><fpage>3223</fpage><lpage>3230</lpage><pub-id pub-id-type="pmid">16963478</pub-id></citation></ref><ref id="R39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McKane</surname><given-names>W</given-names></name><name><surname>Chandna</surname><given-names>SM</given-names></name><name><surname>Tattersall</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD</article-title><source>Kidney Int</source><year>2002</year><volume>61</volume><fpage>256</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">11786108</pub-id></citation></ref><ref id="R40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chandna</surname><given-names>SM</given-names></name><name><surname>Schulz</surname><given-names>J</given-names></name><name><surname>Lawrence</surname><given-names>C</given-names></name><etal/></person-group><article-title>Is there a rationale for rationing chronic dialysis? A hospital based cohort study of factors affecting survival and morbidity</article-title><source>BMJ</source><year>1999</year><volume>318</volume><fpage>217</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">9915728</pub-id></citation></ref><ref id="R41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kimmel</surname><given-names>PL</given-names></name><name><surname>Peterson</surname><given-names>RA</given-names></name><name><surname>Weihs</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Psychologic functioning, quality of life, and behavioral compliance in patients beginning hemodialysis</article-title><source>J Am Soc Nephrol</source><year>1996</year><volume>7</volume><fpage>2152</fpage><lpage>2159</lpage><pub-id pub-id-type="pmid">8915975</pub-id></citation></ref><ref id="R42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanz Guajardo</surname><given-names>D</given-names></name><name><surname>Orte</surname><given-names>L</given-names></name><name><surname>G&#x000f3;mez-Campder&#x000e1;</surname><given-names>F</given-names></name><etal/><collab>INESIR Group</collab></person-group><article-title>Calidad de vida en los pacientes con insuficiencia renal cronica. Influencia de la intervencion precoz del nefrologo y de la consulta predialisis</article-title><source>Nefrologia</source><year>2006</year><volume>26</volume><issue>Suppl 3</issue><fpage>56</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">17469429</pub-id></citation></ref><ref id="R43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez Revuelta</surname><given-names>K</given-names></name><name><surname>Garc&#x000ed;a L&#x000f3;pez</surname><given-names>FJ</given-names></name><name><surname>de Alvaro Moreno</surname><given-names>F</given-names></name><etal/></person-group><article-title>Perceived mental health at the start of dialysis as a predictor of morbidity and mortality in patients with end-stage renal disease (CALVIDIA Study)</article-title><source>Nephrol Dial Transplant</source><year>2004</year><volume>19</volume><fpage>2347</fpage><lpage>2353</lpage><pub-id pub-id-type="pmid">15252167</pub-id></citation></ref><ref id="R44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pisoni</surname><given-names>RL</given-names></name><name><surname>Young</surname><given-names>EW</given-names></name><name><surname>Dykstra</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Vascular access use in Europe and the United States: results from the DOPPS</article-title><source>Kidney Int</source><year>2002</year><volume>61</volume><fpage>305</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">11786113</pub-id></citation></ref><ref id="R45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez Hern&#x000e1;ndez</surname><given-names>JA</given-names></name><name><surname>L&#x000f3;pez Pedret</surname><given-names>J</given-names></name><name><surname>Piera</surname><given-names>L</given-names></name></person-group><article-title>El acceso vascular en Espa&#x000f1;a: an&#x000e1;lisis de su distribuci&#x000f3;n, morbilidad y sistemas de monitorizaci&#x000f3;n</article-title><source>Nefrologia</source><year>2001</year><volume>21</volume><fpage>45</fpage><lpage>51</lpage></citation></ref><ref id="R46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez</surname><given-names>JA</given-names></name><name><surname>Armadans</surname><given-names>L</given-names></name><name><surname>Ferrer</surname><given-names>E</given-names></name><etal/></person-group><article-title>The function of permanent vascular access</article-title><source>Nephrol Dial Transplant</source><year>2000</year><volume>15</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">10692528</pub-id></citation></ref><ref id="R47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez</surname><given-names>JA</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>J</given-names></name><name><surname>Piera</surname><given-names>L</given-names></name></person-group><article-title>El acceso vascular en Espa&#x000f1;a: an&#x000e1;lisis de su distribuci&#x000f3;n, morbilidad y sistemas de monitorizaci&#x000f3;n</article-title><source>Nefrolog&#x000ed;a</source><year>2001</year><volume>21</volume><fpage>45</fpage><lpage>51</lpage></citation></ref><ref id="R48"><label>48</label><citation citation-type="other"><person-group person-group-type="author"><collab>RMRC: Informe Estadistic 2000</collab></person-group><year>2001</year><comment>Servei Catal&#x000e0; de la Salut. Departament de Sanitat i Seguretat Social. Barcelona</comment></citation></ref><ref id="R49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valderr&#x000e1;bano</surname><given-names>F</given-names></name><name><surname>H&#x000f6;rl</surname><given-names>WH</given-names></name><name><surname>Macdougall</surname><given-names>IC</given-names></name><etal/></person-group><article-title>PRE-dialysis survey on anaemia management</article-title><source>Nephrol Dial Transplant</source><year>2003</year><volume>18</volume><fpage>89</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">12480965</pub-id></citation></ref><ref id="R50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f3;mez-Campder&#x000e1;</surname><given-names>FJ</given-names></name><name><surname>Orte</surname><given-names>L</given-names></name><name><surname>Aguilar</surname><given-names>MD</given-names></name><etal/><collab>INESIR Group</collab></person-group><article-title>Situaci&#x000f3;n cl&#x000ed;nica del paciente en el momento de iniciar di&#x000e1;lisis. Estudio INESIR</article-title><source>Nefrologia</source><year>2006</year><volume>26</volume><issue>Suppl 3</issue><fpage>12</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">17469422</pub-id></citation></ref><ref id="R51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rayner</surname><given-names>HC</given-names></name><name><surname>Besarab</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>WW</given-names></name><etal/></person-group><article-title>Vascular access results from the Dialysis Outcomes and Practice Patterns Study (DOPPS): performance against Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines</article-title><source>Am J Kidney Dis</source><year>2004a</year><volume>44</volume><issue>Suppl 2</issue><fpage>S22</fpage><lpage>S26</lpage></citation></ref><ref id="R52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lorenzo</surname><given-names>V</given-names></name><name><surname>Martn</surname><given-names>M</given-names></name><name><surname>Rufino</surname><given-names>M</given-names></name><etal/></person-group><article-title>Predialysis nephrologic care and a functioning arteriovenous fistula at entry are associated with better survival in incident hemodialysis patients: an observational cohort study</article-title><source>Am J Kidney Dis</source><year>2004</year><volume>43</volume><fpage>999</fpage><lpage>1007</lpage><pub-id pub-id-type="pmid">15168379</pub-id></citation></ref><ref id="R53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ifudu</surname><given-names>O</given-names></name><name><surname>Dawood</surname><given-names>M</given-names></name><name><surname>Homel</surname><given-names>P</given-names></name><etal/></person-group><article-title>Excess morbidity in patients starting uremia therapy without prior care by a nephrologist</article-title><source>Am J Kidney Dis</source><year>1996</year><volume>28</volume><fpage>841</fpage><lpage>845</lpage><pub-id pub-id-type="pmid">8957035</pub-id></citation></ref><ref id="R54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roubicek</surname><given-names>C</given-names></name><name><surname>Brunet</surname><given-names>P</given-names></name><name><surname>Huiart</surname><given-names>L</given-names></name><etal/></person-group><article-title>Timing of nephrology referral: influence on mortality and morbidity</article-title><source>Am J Kidney Dis</source><year>2000</year><volume>36</volume><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">10873869</pub-id></citation></ref><ref id="R55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Castellano</surname><given-names>I</given-names></name><name><surname>Gallego</surname><given-names>S</given-names></name><name><surname>Labrador</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Comienzo de tratamiento renal sustitutivo en la provincia de Caceres</article-title><source>Nefrologia</source><year>2006</year><volume>26</volume><fpage>379</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">16892828</pub-id></citation></ref><ref id="R56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><collab>National Kidney Foundation</collab></person-group><article-title>NKF-K/DOQI Clinical Practice Guidelines for Hemodialysis Adequacy: update 2000</article-title><source>Am J Kidney Dis</source><year>2001</year><volume>37</volume><issue>Suppl 1</issue><fpage>S7</fpage><lpage>S64</lpage></citation></ref><ref id="R57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Korevaar</surname><given-names>JC</given-names></name><name><surname>Jansen</surname><given-names>MA</given-names></name><name><surname>Dekker</surname><given-names>FW</given-names></name><etal/><collab>Netherlands Cooperative Study on the Adequacy of Dialysis Study Group</collab></person-group><article-title>When to initiate dialysis: effect of proposed US guidelines on survival</article-title><source>Lancet</source><year>2001</year><volume>358</volume><fpage>1046</fpage><lpage>1050</lpage><pub-id pub-id-type="pmid">11589934</pub-id></citation></ref><ref id="R58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Locatelli</surname><given-names>F</given-names></name><name><surname>Pisoni</surname><given-names>RL</given-names></name><name><surname>Combe</surname><given-names>C</given-names></name><etal/></person-group><article-title>Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)</article-title><source>Nephrol Dial Transplant</source><year>2004</year><volume>19</volume><fpage>121</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">14671047</pub-id></citation></ref><ref id="R59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Longenecker</surname><given-names>JC</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Powe</surname><given-names>NR</given-names></name><etal/></person-group><article-title>Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study</article-title><source>J Am Soc Nephrol</source><year>2002</year><volume>13</volume><fpage>1918</fpage><lpage>1927</lpage><pub-id pub-id-type="pmid">12089389</pub-id></citation></ref><ref id="R60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manresa</surname><given-names>JM</given-names></name><name><surname>Zamora</surname><given-names>A</given-names></name><name><surname>Tom&#x000e1;s</surname><given-names>M</given-names></name><etal/></person-group><article-title>Relationship of classical and non-classical risk factors with genetic variants relevant to coronary heart disease</article-title><source>Eur J Cardiovasc Prev Rehabil</source><year>2006</year><volume>13</volume><fpage>738</fpage><lpage>744</lpage><pub-id pub-id-type="pmid">17001213</pub-id></citation></ref><ref id="R61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bostom</surname><given-names>AG</given-names></name><name><surname>Shemin</surname><given-names>D</given-names></name><name><surname>Verhoef</surname><given-names>P</given-names></name><etal/></person-group><article-title>Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study</article-title><source>Arterioscler Thromb Vasc Biol</source><year>1997</year><volume>17</volume><fpage>2554</fpage><lpage>2558</lpage><pub-id pub-id-type="pmid">9409227</pub-id></citation></ref><ref id="R62"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>EW</given-names></name><name><surname>Akiba</surname><given-names>T</given-names></name><name><surname>Albert</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)</article-title><source>Am J Kidney Dis</source><year>2004</year><volume>44</volume><issue>Suppl 2</issue><fpage>34</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">15486872</pub-id></citation></ref><ref id="R63"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Foley</surname><given-names>RN</given-names></name><name><surname>Collins</surname><given-names>AJ</given-names></name></person-group><article-title>End-stage renal disease in the United States: an update from the United States Renal Data System</article-title><source>J Am Soc Nephrol</source><year>2007</year><volume>18</volume><fpage>2644</fpage><lpage>2648</lpage><pub-id pub-id-type="pmid">17656472</pub-id></citation></ref></ref-list></back></article>